[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 95 of about 95
1. Nakagawa TL, Sakai H, Yanai T, Kitoh K, Mori T, Murakami M, Masegi T: Simultaneous aortic body tumor and pulmonary histiocytic sarcoma in a flat-coated retriever. J Vet Med Sci; 2009 Sep;71(9):1221-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous aortic body tumor and pulmonary histiocytic sarcoma in a flat-coated retriever.
  • A case of multiple primary tumors observed in the heart base and in the lung of a 7-year-old intact female, flat-coated retriever was reported.
  • Morphological differences between both tumors and detailed immunohistochemical study revealed that the cardiac neoplasm was as a malignant aortic body tumor and the lung tumor was a pulmonary histiocytic sarcoma.
  • The occurrence of aortic body tumor with other primary neoplasms has been previously reported in animals suggesting that this might be a common presentation in dogs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801903.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Kim SK, Hyun CB, Cho KO: Unusual metastasis of malignant aortic body tumor to multiple bones in a dog. J Vet Med Sci; 2005 Jun;67(6):625-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual metastasis of malignant aortic body tumor to multiple bones in a dog.
  • Unusual metastasis of malignant aortic body tumor to multiple bones was detected in a 5-year-old female English Setter dog.
  • Radiographs exhibited an abnormal mass in the base of heart and osteolytic lesions in the bodies of T11 and L2 vertebrates, body of right femur, right proximal humoral epiphysis and infraspinous fossa near to the neck of right scapula.
  • At necropsy, multiple tumor masses of various sizes were observed also in the bones as well as the heart base and tracheobronchial lymph node.
  • Tumor masses of L2 and T11 protruded into the vertebral canal and compressed corresponding sites of spinal cord, leading to paraplegia.
  • Histopathologically, the tumor cells, arranged in sheets or nests, were polyhedral, lightly eosinophilic, finely granular cytoplasm with mostly round to oval nucleus and had scattered bizarre giant cells.
  • Ultrastructural study revealed the characteristic findings that tumor cells contained a large number of small, electron-dense, membrane-limited secretory granules in cytoplasm.
  • This is thought to be an extremely rare case having multiple bone metastases of a malignant aortic body tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997194.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Aresu L, Tursi M, Iussich S, Guarda F, Valenza F: Use of s-100 and chromogranin a antibodies as immunohistochemical markers on detection of malignancy in aortic body tumors in dog. J Vet Med Sci; 2006 Nov;68(11):1229-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of s-100 and chromogranin a antibodies as immunohistochemical markers on detection of malignancy in aortic body tumors in dog.
  • To define the characteristics of malignancy we performed routine histology and an immunohistochemical study on seventeen aortic body tumors in dogs.
  • The sustentacular cells density and chief cell staining intensity were both inversely related to tumor grade.
  • This report indicates that the immunohistochemical panel has utility for the diagnosis of chemodectoma and the negative staining to CrA and S-100 markers in tumors grade III expresses an indication of malignant behaviour of the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146187.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / S100 Proteins
  •  go-up   go-down


Advertisement
4. Wang S, Wu D, Matthan NR, Lamon-Fava S, Lecker JL, Lichtenstein AH: Enhanced aortic macrophage lipid accumulation and inflammatory response in LDL receptor null mice fed an atherogenic diet. Lipids; 2010 Aug;45(8):701-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced aortic macrophage lipid accumulation and inflammatory response in LDL receptor null mice fed an atherogenic diet.
  • The effect of an atherogenic diet on inflammatory response and elicited peritoneal macrophage (Mphi) cholesterol accumulation in relation to aortic lesion formation was assessed in LDL receptor null (LDLr-/-) mice.
  • The atherogenic relative to control diet resulted in significantly higher plasma monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6) concentrations, more aortic wall Mphi deposition, higher serum non HDL-cholesterol concentrations and total cholesterol to HDL-cholesterol ratios, and greater accumulation of both aortic free and esterified cholesterol.
  • These data suggest that the atherogenic relative to control diet resulted in higher plasma inflammatory factor concentrations, less favorable lipoprotein profile, higher elicited peritoneal Mphi cholesterol accumulation and inflammatory factor secretion, and more aortic wall Mphi deposition, which in turn were associated with greater aortic cholesterol accumulation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Immunol. 2005 Feb;114(2):100-9 [15639643.001]
  • [Cites] Circulation. 2004 Dec 7;110(23):3604-9 [15569842.001]
  • [Cites] J Nutr. 2005 Mar;135(3):492-8 [15735083.001]
  • [Cites] Atheroscler Suppl. 2005 May;6(2):21-9 [15823493.001]
  • [Cites] Obes Res. 2005 Aug;13(8):1311-20 [16129712.001]
  • [Cites] Nature. 2005 Sep 29;437(7059):759-63 [16127449.001]
  • [Cites] Atherosclerosis. 2005 Dec;183(2):301-7 [16285993.001]
  • [Cites] Circ J. 2005 Dec;69(12):1484-9 [16308496.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 24;340(4):1078-84 [16403442.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):610-21 [16467548.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 May;26(5):995-1001 [16484595.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 7;345(3):1004-9 [16712797.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1494-505 [16691291.001]
  • [Cites] Nutr Rev. 2000 Feb;58(2 Pt 1):56-9 [10748610.001]
  • [Cites] Atherosclerosis. 2000 Sep;152(1):43-50 [10996338.001]
  • [Cites] Cell. 2001 Feb 23;104(4):503-16 [11239408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):507-12 [11149950.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38378-87 [11504730.001]
  • [Cites] Circulation. 2001 Dec 18;104(25):3103-8 [11748108.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Infect Immun. 2002 Jun;70(6):2995-3003 [12010990.001]
  • [Cites] Circulation. 2002 Oct 8;106(15):1985-90 [12370224.001]
  • [Cites] Prev Med. 2002 Dec;35(6):540-7 [12460521.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1702-11 [16728653.001]
  • [Cites] Am J Clin Nutr. 2006 Sep;84(3):497-504 [16960162.001]
  • [Cites] Cytokine. 2006 Sep;35(5-6):258-62 [17070067.001]
  • [Cites] Atherosclerosis. 2007 Mar;191(1):11-21 [16730733.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5207-16 [17186944.001]
  • [Cites] Nat Rev Immunol. 2008 Jul;8(7):523-32 [18566595.001]
  • [Cites] Atherosclerosis. 2009 May;204(1):147-55 [18842266.001]
  • [Cites] Br J Nutr. 2009 Aug;102(4):497-501 [19660150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11529-30 [15292506.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49982-8 [12376530.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):10983-92 [12529332.001]
  • [Cites] J Lipid Res. 2003 Apr;44(4):800-6 [12562840.001]
  • [Cites] Atherosclerosis. 2003 Oct;170(2):277-83 [14612208.001]
  • [Cites] Biochem J. 2004 Feb 1;377(Pt 3):545-52 [14604434.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):969-73 [15159225.001]
  • [Cites] Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10 [15173056.001]
  • [Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III20-6 [15198962.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):1029-35 [15447916.001]
  • [Cites] Circ Res. 2004 Oct 29;95(9):858-66 [15514167.001]
  • [Cites] Eur J Med Res. 1997 Jun 16;2(6):243-57 [9182652.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):79-82 [9422508.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):82-6 [9422509.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 1):C661-8 [9730949.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):275-81 [9734366.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1818-27 [9812923.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):29-33 [10092505.001]
  • [Cites] Atherosclerosis. 1999 Jul;145(1):51-60 [10428295.001]
  • [Cites] J Clin Invest. 1999 Oct;104(8):R25-31 [10525055.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):e174-8 [15331433.001]
  • [Cites] Atherosclerosis. 2004 Dec;177(2):313-20 [15530905.001]
  • [Cites] Clin Chem Lab Med. 2004;42(10):1132-9 [15552272.001]
  • [Cites] Eur J Clin Invest. 2005 Jan;35(1):52-9 [15638820.001]
  • (PMID = 20686867.001).
  • [ISSN] 1558-9307
  • [Journal-full-title] Lipids
  • [ISO-abbreviation] Lipids
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL054727-07; United States / NHLBI NIH HHS / HL / R01 HL 54727; United States / NHLBI NIH HHS / HL / HL054727-04; United States / NHLBI NIH HHS / HL / R01 HL054727-06; United States / NHLBI NIH HHS / HL / R01 HL054727-04; United States / NHLBI NIH HHS / HL / R01 HL054727-05; United States / NHLBI NIH HHS / HL / T32 HL69772-01A1; United States / NHLBI NIH HHS / HL / T32 HL069772; United States / NHLBI NIH HHS / HL / T32 HL069772-01A1; United States / NHLBI NIH HHS / HL / HL054727-07; United States / NHLBI NIH HHS / HL / R01 HL054727-03; United States / NHLBI NIH HHS / HL / HL054727-06; United States / NHLBI NIH HHS / HL / HL054727-05; United States / NHLBI NIH HHS / HL / HL054727-03; United States / NHLBI NIH HHS / HL / R01 HL054727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lipids; 0 / Receptors, LDL
  • [Other-IDs] NLM/ NIHMS231280; NLM/ PMC2935317
  •  go-up   go-down


5. Shaw TE, Harkin KR, Nietfeld J, Gardner JJ: Aortic body tumor in full-sibling English bulldogs. J Am Anim Hosp Assoc; 2010 Sep-Oct;46(5):366-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortic body tumor in full-sibling English bulldogs.
  • An aortic body tumor was the cause of death in both dogs based on postmortem and histological examinations.
  • Neither dog had a history of brachycephalic airway syndrome, and the implication for a genetic predisposition toward the development of paraganglioma is discussed.
  • This is the first case report of aortic body tumors in sibling dogs, although the condition may not be an uncommon phenomenon.
  • [MeSH-major] Aortic Bodies / pathology. Dog Diseases / diagnosis. Nervous System Neoplasms / veterinary
  • [MeSH-minor] Animals. Breeding. Dogs. Dyspnea / diagnosis. Dyspnea / etiology. Dyspnea / veterinary. Fatal Outcome. Female. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20810559.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Tognolini A, Schor-Bardach R, Pianykh OS, Wilcox CJ, Raptopoulos V, Goldberg SN: Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model. Radiology; 2009 Jun;251(3):712-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model.
  • PURPOSE: To evaluate the effects of total scanning time (TST), interscan delay (ISD), inclusion of image at peak vascular enhancement (IPVE), and selection of the input function vessel on the accuracy of tumor blood flow (BF) calculation with computed tomography (CT) in an animal model.
  • CONCLUSION: To reduce radiation dose in tumor perfusion with CT, TST can be reduced without causing significant changes in BF calculation in an animal model.
  • Scanning the aortic reference with peak contrast enhancement reduces variability sufficiently to allow for longer ISDs.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2003 Apr;76(904):220-31 [12711641.001]
  • [Cites] J Surg Oncol. 2007 Sep 1;96(3):220-9 [17450532.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1188-90; author reply 1188-90 [14503542.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Jan;25(1):97-107 [14729537.001]
  • [Cites] Acad Radiol. 2004 Feb;11(2):215-23 [14974597.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 May;25(5):720-9 [15140710.001]
  • [Cites] J Nucl Med. 1983 Jul;24(7):577-81 [6602868.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):185-90 [11884771.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Feb;50(2):159-67 [12665029.001]
  • [Cites] Med Phys. 1984 Sep-Oct;11(5):690-2 [6390118.001]
  • [Cites] Magn Reson Q. 1989 Oct;5(4):263-81 [2701285.001]
  • [Cites] Phys Med Biol. 1992 Sep;37(9):1741-58 [1409870.001]
  • [Cites] J Appl Physiol. 1954 Jun;6(12):731-44 [13174454.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Dec;23(12):1532-42 [15575410.001]
  • [Cites] Radiology. 2005 Mar;234(3):785-92 [15734934.001]
  • [Cites] World J Gastroenterol. 2005 Mar 7;11(9):1287-91 [15761965.001]
  • [Cites] Radiat Med. 2005 Aug;23(5):351-63 [16342908.001]
  • [Cites] Radiat Med. 2005 Aug;23(5):364-70 [16342909.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):101-6 [16418366.001]
  • [Cites] Abdom Imaging. 2006 Mar-Apr;31(2):194-9 [16333695.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] AJR Am J Roentgenol. 2006 Oct;187(4):1079-84 [16985160.001]
  • [Cites] Radiology. 2007 Jun;243(3):712-9 [17517930.001]
  • [Cites] Q J Nucl Med. 2003 Sep;47(3):171-87 [12897709.001]
  • (PMID = 19304916.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA101942-01; United States / NCI NIH HHS / CA / 1R01CA112533-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2687528
  •  go-up   go-down


7. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, Gaze D, Nasr H, Loftus IM, Thompson MM, Cockerill GW: Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation; 2009 Jun 23;119(24):3125-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.
  • BACKGROUND: Development and rupture of aortic aneurysms involve a combination of complex biological processes.
  • At day 28, aortic size was measured, and tissues were collected for analyses.
  • Blood glucose, total cholesterol, body weight, and atherosclerosis did not differ between groups.
  • Pretreatment with rosiglitazone inhibited the Ang II-induced expression of angiotensin type 1a Ang II receptor while having no effect on the angiotensin type 2 Ang II receptor, in addition to reducing Ang II-induced expression of E-selectin, tumor necrosis factor-alpha, and interleukin-6.
  • CONCLUSIONS: Pretreatment or posttreatment with RGZ reduced aortic expansion and rupture in this mouse model.
  • [MeSH-major] Aortic Aneurysm, Abdominal / prevention & control. Aortic Rupture / prevention & control. Hypoglycemic Agents / pharmacology. Thiazolidinediones / pharmacology
  • [MeSH-minor] Angiotensin II / adverse effects. Angiotensin II / pharmacology. Animals. Apolipoproteins E / genetics. Apolipoproteins E / metabolism. Blood Glucose / analysis. Body Weight / drug effects. Cholesterol / blood. Disease Models, Animal. E-Selectin / blood. Humans. Hypercholesterolemia / blood. Hypercholesterolemia / chemically induced. Hypercholesterolemia / genetics. Hypercholesterolemia / pathology. Hypercholesterolemia / prevention & control. Interleukin-6 / blood. Mice. Mice, Knockout. PPAR gamma / agonists. PPAR gamma / genetics. PPAR gamma / metabolism. Receptors, Angiotensin / blood. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506106.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Blood Glucose; 0 / E-Selectin; 0 / Hypoglycemic Agents; 0 / Interleukin-6; 0 / PPAR gamma; 0 / Receptors, Angiotensin; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 05V02F2KDG / rosiglitazone; 11128-99-7 / Angiotensin II; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


8. Into T, Kanno Y, Dohkan J, Nakashima M, Inomata M, Shibata K, Lowenstein CJ, Matsushita K: Pathogen recognition by Toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells. J Biol Chem; 2007 Mar 16;282(11):8134-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogen recognition by Toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells.
  • The endothelial cell-specific granule Weibel-Palade body releases vasoactive substances capable of modulating vascular inflammation.
  • We here report that human aortic endothelial cells respond to bacterial lipoteichoic acid (LTA) and synthetic bacterial lipopeptides, but not lipopolysaccharide or peptidoglycan, to induce Weibel-Palade body exocytosis, accompanied by release or externalization of the storage components von Willebrand factor and P-selectin.
  • LTA could activate rapid Weibel-Palade body exocytosis through a TLR2- and MyD88-dependent mechanism without de novo protein synthesis.
  • Increased TLR2 expression by transfection or interferon-gamma treatment increased TLR2-mediated Weibel-Palade body exocytosis, whereas reduced TLR2 expression under laminar flow decreased the response.
  • Thus, we propose a novel role for TLR2 in induction of a primary proinflammatory event in aortic endothelial cells through Weibel-Palade body exocytosis, which may be an important step for linking innate recognition of bacterial pathogens to vascular inflammation.
  • [MeSH-minor] Cell Line. Exocytosis. Humans. Interferon-gamma / pharmacology. Lipopolysaccharides / pharmacology. Protein Binding. Teichoic Acids / pharmacology. Toll-Like Receptor 4 / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227763.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / TLR2 protein, human; 0 / TLR4 protein, human; 0 / Teichoic Acids; 0 / Toll-Like Receptor 2; 0 / Toll-Like Receptor 4; 0 / Tumor Necrosis Factor-alpha; 56411-57-5 / lipoteichoic acid; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


9. Binning MJ, Sarfati MR, Couldwell WT: Embolic atrial myxoma causing aortic and carotid occlusion. Surg Neurol; 2009 Feb;71(2):246-9; discussion 249
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embolic atrial myxoma causing aortic and carotid occlusion.
  • Cardiac myxoma can embolize to multiple sites throughout the body.
  • Pathologic studies confirmed the diagnosis of cardiac myxoma.
  • CONCLUSIONS: This is the first case reported in the English literature of simultaneous aortic and internal carotid artery occlusion from embolism of an atrial myxoma without evidence of intracardiac tumor on transesophageal echocardiogram.

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18295838.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Mithani SK, Marohn MR, Freischlag JA, Dackiw AP, Zeiger MA: Laparoscopic resection of a paraganglioma of the organ of Zuckerkandl in a patient with a carotid body tumor. Am Surg; 2006 Jan;72(1):55-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection of a paraganglioma of the organ of Zuckerkandl in a patient with a carotid body tumor.
  • Synchronous paraganglioma occur sporadically, and on occasion, in association with several genetic syndromes.
  • Paraganglioma of the organ of Zuckerkandl with synchronous carotid body paraganglioma is described herein.
  • Traditionally, surgical resection of abdominal paraganglioma involved an exploratory laparotomy.
  • In this manuscript, we describe one of the first reported laparoscopic resections of this tumor and review the literature on multiple paragangliomas and their associated genetic syndromes.
  • [MeSH-major] Laparotomy / methods. Neoplasms, Multiple Primary / pathology. Para-Aortic Bodies / pathology. Paraganglioma / surgery
  • [MeSH-minor] Adult. Carotid Body Tumor / pathology. Carotid Body Tumor / radiography. Diagnosis, Differential. Female. Humans. Magnetic Resonance Angiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carotid Body Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494184.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry RC, Johnstone PA: Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol; 2009 Dec;93(3):408-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites.
  • BACKGROUND AND PURPOSE: We report frequency of brachial plexopathy in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy.
  • Thirty-seven lesions in 36 patients were identified as apical lesions, defined as epicenter of lesion superior to aortic arch.
  • RESULTS: The 37 apical lesions (19 Stage IA, 16 IB, and 2 IIB) were treated with stereotactic body radiotherapy to a median total dose of 57 Gy (30-72).
  • CONCLUSIONS: Stereotactic body radiotherapy for apical lesions carries a risk of brachial plexopathy.

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2010 Mar;94(3):388 [20189257.001]
  • (PMID = 19454366.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


12. Menzel T, Peters K, Hammerschmidt S, Ritter O: Metastatic signet ring cell gastric carcinoma presenting as an infrarenal aortic aneurysm. Gastric Cancer; 2005;8(1):47-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic signet ring cell gastric carcinoma presenting as an infrarenal aortic aneurysm.
  • Occasionally, metastases to other parts of the body, such as the prostate gland [1] the gluteal muscle [2], or the cervix [3] are described.
  • We report an unusual case of a signet ring cell gastric carcinoma, initially presenting as an infrarenal aortic aneurysm.
  • Following resection of the aneurysm, the spread of lymphangiosis carcinomatosa into the aortic wall and infiltration of signet ring cells into an adjacent lymph node were noted.
  • The primary tumor, a signet ring cell gastric carcinoma, was detected by a subsequent esophago-gastro-duodenoscopy.
  • [MeSH-major] Aortic Aneurysm / etiology. Carcinoma, Signet Ring Cell / complications. Carcinoma, Signet Ring Cell / pathology. Lymphatic Metastasis. Stomach Neoplasms / complications. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15747175.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Qedra N, Kadry M, Buz S, Meyer R, Ewert P, Hetzer R: Aorticopulmonary paraganglioma with severe obstruction of the pulmonary artery: successful combined treatment by stenting and surgery. Ann Thorac Surg; 2009 Apr;87(4):1284-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aorticopulmonary paraganglioma with severe obstruction of the pulmonary artery: successful combined treatment by stenting and surgery.
  • Aorticopulmonary paraganglioma is a rare tumor of the middle mediastinum.
  • Complete surgical resection is the only effective treatment, even when it may pose a surgical challenge due to the proximity of the tumor to the heart and great vessels, often rendering complete resection difficult to achieve.
  • We report the case of a 30-year-old woman with an aorticopulmonary paraganglioma who presented with severe pulmonary hypertension due to obstruction of the pulmonary artery.
  • In the first step, stenting of the pulmonary artery was performed and 2 months later a radical resection of the tumor using cardiopulmonary bypass under circulatory arrest and deep hypothermia was carried out.
  • In addition, the ascending aorta and aortic arch were replaced by a prosthesis.
  • We believe that this is the first description in the English literature of a successful combined management strategy in view of such an unusual manifestation of aorticopulmonary paraganglioma.
  • [MeSH-major] Arterial Occlusive Diseases / surgery. Blood Vessel Prosthesis Implantation. Paraganglioma / surgery. Pulmonary Artery. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324176.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Gabriel EA, Locali RF, Romano CC, Duarte AJ, Palma JH, Buffolo E: Analysis of the inflammatory response in endovascular treatment of aortic aneurysms. Eur J Cardiothorac Surg; 2007 Mar;31(3):406-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the inflammatory response in endovascular treatment of aortic aneurysms.
  • OBJECTIVE: The objective of this study is to evaluate the inflammatory response caused by endovascular stents in the treatment of aortic aneurysms.
  • The evolution of mediators (sedimentation velocity, C reactive protein, interleukin-6, interleukin-8, tumor necrosis factor-alpha, intercellular adhesion molecule-1, l-selectin), inflammatory cells (leukocytes, lymphocytes, platelets), serum creatinine and body temperature within preoperative period and in the following postoperative periods--1, 6, 24 and 48 h, 7 days, 1-3 months, was analyzed.
  • Tumor necrosis factor-alpha and interleukin-8 did not show statistically significant variability during the entire follow-up.
  • This could help in the analysis of the inflammatory response evolution caused by endovascular stent treatment for aortic aneurysms in premature and late phases after implantation of the vascular prosthesis.
  • [MeSH-major] Aortic Aneurysm / surgery. Blood Vessel Prosthesis Implantation / adverse effects. Inflammation / etiology. Inflammation Mediators / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aortic Aneurysm, Abdominal / surgery. Aortic Aneurysm, Thoracic / surgery. Female. Follow-Up Studies. Humans. Intercellular Adhesion Molecule-1 / blood. Interleukin-6 / blood. Interleukin-8 / blood. L-Selectin / blood. Male. Middle Aged. Stents / adverse effects. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Mar;31(3):412-3 [17267231.001]
  • (PMID = 17215133.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 126880-86-2 / L-Selectin
  •  go-up   go-down


15. Dúbrava J, Garay R: [The role of transesophageal echocardiopgraphy in detection of cardiogenic and aortic sources of embolism in stroke and transient ischaemic attacks]. Vnitr Lek; 2006 Feb;52(2):144-51
MedlinePlus Health Information. consumer health - Transient Ischemic Attack.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of transesophageal echocardiopgraphy in detection of cardiogenic and aortic sources of embolism in stroke and transient ischaemic attacks].
  • OBJECTIVES: To prospectively investigate the prevalence of definite and potential sources of cardiogenic embolism and embolism from ascending aorta and aortic arch in patients with a cryptogenic stroke or transient ischaemic attack (TIA).
  • Less frequently found were mobile thrombus of aortic arch - 3.7%, thrombus of LA body - 2.3%, left ventricular thrombus - 2.3%, thrombus of valvular prosthesis - 1.4% and heart tumor - 0.5%.
  • Very frequently were found patent foramen ovale - 58.3% and atherosclerosis of ascending aorta or aortic arch - 53.7%.
  • Further sources were LA spontaneous echocontrast - 21.1%, reduced function of LA appendage - 18.3%, atrial septal aneurysm - 7.8%, atrial septal defect - 1.4%, cardiac foreign body - 0.5%.
  • 21.6% of the patients suffering from stroke/TIA without hemodynamically significant stenoses of extracranial cerebral arteries had a definite cardiogenic or aortic source of embolism, 2. additional 52.3% of patients had only potential source of embolism (without definite source), 3. we consider TEE necessary in patients with stroke/TIA without a known etiology, despite complete neurological examination and transthoracic echocardography.


16. Ekuni D, Tomofuji T, Irie K, Kasuyama K, Umakoshi M, Azuma T, Tamaki N, Sanbe T, Endo Y, Yamamoto T, Nishida T, Morita M: Effects of periodontitis on aortic insulin resistance in an obese rat model. Lab Invest; 2010 Mar;90(3):348-59
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of periodontitis on aortic insulin resistance in an obese rat model.
  • However, the effects of periodontitis on atherosclerosis in an obese body remain unclear.
  • The aim of the study was to investigate the effects of ligature-induced periodontitis in Zucker fatty rats on initiation of atherosclerosis by evaluating aortic insulin resistance.
  • Levels of serum C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), and insulin were also measured.
  • Periodontitis in obesity induced the initial stage of atherosclerosis and disturbed aortic insulin signaling.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065945.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


17. Teh BS, Paulino AC, Lu HH, Chiu JK, Richardson S, Chiang S, Amato R, Butler EB, Bloch C: Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites. Technol Cancer Res Treat; 2007 Aug;6(4):347-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites.
  • Two years later, we started an extra-cranial stereotactic radio-ablation or more appropriately a stereotactic body radiation therapy (SBRT) program using the Brainlab Novalis image-guided system at The Methodist Hospital in Houston, Texas.
  • Primary or metastatic lesions located in the head and neck, supraclavicular region, axilla, mediastinum, lung (both central and peripheral), abdominal wall, liver, kidney, para-aortic lymph nodes, prostate, and pelvis were also treated.
  • Treating these sites safely and efficaciously requires knowledge in radiation tolerance, fraction size, total dose, biologically equivalent dose (BED), prior radiotherapy, detailed dose volume histograms (DVH) of normal tissues, and the radiosensitive/radioresistant nature of the tumor.
  • Tumor/organ motion data obtained using 4D-CT while the patient is immobilized in the body cast aids in planning treatment margin and determining the need for respiratory motion control, e.g., abdominal compressor, gating, or active breathing control.
  • Appropriate use of immobilization devices, radio-opaque markers for image-guidance, 4D-CT for tumor/organ motion estimates, and fusion of planning CT scans with biological/functional imaging will further improve the planning and delivery of SBRT, hopefully leading to better treatment outcome.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668943.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Choudry HA, Souba WW, Lin C, Meng Q, Karinch AM, Huang J, Pan M: Stimulation of expression of the intestinal glutamine transporter ATB0 in tumor-bearing rats. Ann Surg Oncol; 2006 Dec;13(12):1747-53
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of expression of the intestinal glutamine transporter ATB0 in tumor-bearing rats.
  • BACKGROUND: Glutamine supplementation ameliorates host catabolic response in tumor bearing states.
  • METHODS: Fisher-344 rats underwent subcutaneous flank implantation of MCA-sarcoma cells (saline as control) and were pair-fed an equal quantity of chow as controls, to account for tumor-induced anorexia, until tumors reached 10 or 20% body weight.
  • RESULTS: Glutamine transport activity across the intestinal brush border membrane (BBM) was 3.7-fold higher in tumor-bearing rats (TBR) than in controls (TBR 153 +/- 22.6 vs.
  • Transporter ATB(0) mRNA levels were 1.4-fold higher in tumor-bearing rats (Relative value TBR .61 +/- .12 vs. Control .43 +/- .1, P < .05).
  • A 1.4-fold increase in transporter ATB(0) protein levels was observed in the tumor-bearing rats (Relative value TBR .52 +/- .07 vs. Control .37 +/- .04, P < .05).
  • Circulating aortic plasma glutamine levels were 1.3-fold higher in tumor bearing rats ([Glutamine] = .63 +/- .02 Control vs. [Glutamine] = .74 +/- .01 mmol/l TBR, P < .0001).
  • Portal venous plasma glutamine levels were also higher in tumor bearing rats ([Glutamine] = .47 +/- .01 Control vs. [Glutamine] = .60 +/- .02 mmol/l TBR, P < .0001).
  • CONCLUSION: Intestinal brush border membrane glutamine transport activity, transporter ATB(0) mRNA and protein levels are up-regulate in tumor-bearing rats.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006743.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / RNA, Messenger; 0 / glutamine transport proteins; 0RH81L854J / Glutamine
  •  go-up   go-down


19. Witkowska AM, Borawska MH, Gacko M: Relationship among TNF-alpha, sICAM-1, and selenium in presurgical patients with abdominal aortic aneurysms. Biol Trace Elem Res; 2006;114(1-3):31-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship among TNF-alpha, sICAM-1, and selenium in presurgical patients with abdominal aortic aneurysms.
  • The purpose of our study was to estimate the utility of tumor necrosis factor (TNF), soluble intercellular adhesion molecule-1 (sICAM-1), and selenium (Se) measurements as subsidiary parameters for the diagnosis and differentiation of large aortic abdominal aneurysms (AAAs).
  • TNF was related to body mass index (r = 0.375).
  • [MeSH-major] Aortic Aneurysm, Abdominal / blood. Intercellular Adhesion Molecule-1 / blood. Selenium / blood. Tumor Necrosis Factor-alpha / metabolism

  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17205985.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; H6241UJ22B / Selenium
  •  go-up   go-down


20. Kastellanos SS, Toumpoulis IK, Aggeli C, Zezas S, Chlapoutakis E, Kastellanos S, Stefanadis CI: Time course of C-reactive protein, tumour necrosis factor-alpha and monocyte chemoattractant protein-1 following the surgical treatment of patients with aortic valve stenosis. Hellenic J Cardiol; 2007 Jan-Feb;48(1):5-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time course of C-reactive protein, tumour necrosis factor-alpha and monocyte chemoattractant protein-1 following the surgical treatment of patients with aortic valve stenosis.
  • INTRODUCTION: Patients with aortic valve stenosis show elevated levels of inflammatory markers in peripheral blood.
  • The aim of this study was to investigate the time course of changes in these markers and to look for sex-related changes in their biological behaviour following aortic valve replacement.
  • METHODS: We studied 52 patients (32 men, 20 women) who underwent aortic valve replacement and had no concomitant coronary artery disease.
  • Men and women did not differ significantly with respect to age, body surface area, or body mass index.
  • Levels of high sensitivity C-reactive protein (hsCRP), tumour necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1) were measured from venous blood samples taken before, and 10 days, 3 months and 6 months after aortic valve replacement.
  • CONCLUSIONS: After aortic valve replacement, hsCRP levels show an early increase followed by a decrease, whereas both TNF-alpha and MCP-1 are reduced progressively.
  • The time course curve is identical in men and women, except that hsCRP levels are higher in women than in men 6 months after aortic valve replacement.
  • [MeSH-major] Aortic Valve Stenosis / blood. Aortic Valve Stenosis / surgery. C-Reactive Protein / analysis. Chemokine CCL2 / blood. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Aortic Valve Stenosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388104.001).
  • [ISSN] 1109-9666
  • [Journal-full-title] Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē
  • [ISO-abbreviation] Hellenic J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chemokine CCL2; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


21. Yuen DY, Dwyer RM, Matthews VB, Zhang L, Drew BG, Neill B, Kingwell BA, Clark MG, Rattigan S, Febbraio MA: Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes; 2009 May;58(5):1086-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression.
  • RESEARCH DESIGN AND METHODS: The effect of IL-6 with and without insulin on AMPK, insulin, and eNOS signaling in and nitric oxide (NO) release from human aortic endothelial cells (HAECs) was examined.
  • In contrast, IL-6 increased Akt phosphorylation (Ser473) in hindlimb skeletal muscle and enhanced whole-body glucose disappearance and glucose uptake during the clamp.
  • The differences in endothelial cell and skeletal muscle signaling were mediated by the cell-specific, additive effects of IL-6 and insulin because this treatment markedly increased tumor necrosis factor (TNF)-alpha protein expression in HAECs without any effect on TNF-alpha in skeletal muscle.
  • [MeSH-major] Endothelium, Vascular / physiology. Insulin / physiology. Interleukin-6 / pharmacology. Muscle, Skeletal / physiology. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 2000 Mar;49(3):325-31 [10868952.001]
  • [Cites] PLoS Med. 2008 Apr 8;5(4):e78 [18399716.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3338-42 [10999830.001]
  • [Cites] Diabetes. 2000 Nov;49(11):1904-9 [11078458.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Apr;280(4):C769-74 [11245592.001]
  • [Cites] J Physiol. 2001 Jun 1;533(Pt 2):585-91 [11389214.001]
  • [Cites] Obes Res. 2001 Jul;9(7):414-7 [11445664.001]
  • [Cites] J Physiol. 2001 Dec 1;537(Pt 2):633-9 [11731593.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E18-23 [11739078.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):46912-6 [11598104.001]
  • [Cites] Nat Med. 2002 Jan;8(1):75-9 [11786910.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E714-20 [11832377.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1335-47 [12205025.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E241-58 [12531739.001]
  • [Cites] Endocr Rev. 2003 Jun;24(3):278-301 [12788800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10623-8 [12963823.001]
  • [Cites] FASEB J. 2003 Nov;17(14):2166-8 [12958150.001]
  • [Cites] Diabetes. 2004 Feb;53(2):447-53 [14747297.001]
  • [Cites] Diabetes. 2004 Jun;53(6):1418-23 [15161743.001]
  • [Cites] FASEB J. 2004 Jun;18(9):992-4 [15059966.001]
  • [Cites] Diabetologia. 2004 Jun;47(6):1029-37 [15168015.001]
  • [Cites] Diabetologia. 2004 Jul;47(7):1135-42 [15241593.001]
  • [Cites] Am J Physiol. 1985 Mar;248(3 Pt 1):E353-62 [3883806.001]
  • [Cites] Am J Physiol. 1985 May;248(5 Pt 1):E567-74 [3887942.001]
  • [Cites] J Appl Physiol (1985). 1988 May;64(5):1942-6 [3292505.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):1844-52 [2189893.001]
  • [Cites] J Clin Invest. 1996 Aug 15;98(4):894-8 [8770859.001]
  • [Cites] Diabetes. 1997 Sep;46(9):1381-8 [9287035.001]
  • [Cites] FEBS Lett. 1999 Jan 29;443(3):285-9 [10025949.001]
  • [Cites] Nature. 1999 Jun 10;399(6736):601-5 [10376603.001]
  • [Cites] Science. 2005 Jan 21;307(5708):373-5 [15662001.001]
  • [Cites] Nat Med. 2005 Feb;11(2):183-90 [15685173.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1111-9 [15864338.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E251-7 [15755769.001]
  • [Cites] Diabetes. 2005 Dec;54 Suppl 2:S114-24 [16306329.001]
  • [Cites] Nat Med. 2006 May;12(5):541-8 [16604088.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1813-22 [16823479.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2688-97 [17003332.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2791-8 [16981010.001]
  • [Cites] Cell Metab. 2006 Dec;4(6):465-74 [17141630.001]
  • [Cites] Essays Biochem. 2006;42:133-44 [17144885.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2372-83 [17242212.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):841-9 [17404609.001]
  • [Cites] Endocrinology. 2007 Jul;148(7):3356-63 [17446186.001]
  • [Cites] Obes Rev. 2008 Jan;9(1):20-9 [17956545.001]
  • [Cites] FASEB J. 2000 Sep;14(12):1685-96 [10973917.001]
  • (PMID = 19188427.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 31C4KY9ESH / Nitric Oxide; EC 2.7.4.3 / Adenylate Kinase
  • [Other-IDs] NLM/ PMC2671037
  •  go-up   go-down


22. Oceandy D, Pickard A, Prehar S, Zi M, Mohamed TM, Stanley PJ, Baudoin-Stanley F, Nadif R, Tommasi S, Pfeifer GP, Armesilla AL, Cartwright EJ, Neyses L: Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation; 2009 Aug 18;120(7):607-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy.
  • Although it is known that defective Ras signaling is associated with Noonan, Costello, and other syndromes that are characterized by tumor formation and cardiac hypertrophy, little is known about factors that may control it.
  • Ablation of RASSF1A in mice significantly enhanced the hypertrophic response to transverse aortic constriction (64.2% increase in heart weight/body weight ratio in RASSF1A(-)(/)(-) mice compared with 32.4% in wild type).
  • [MeSH-major] Cardiomegaly / metabolism. Cardiomegaly / pathology. Cell Proliferation. Signal Transduction / physiology. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652091.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / BHF/ FS/09/046/28043; United Kingdom / Medical Research Council / / G0200020; United Kingdom / Medical Research Council / / G0500025; United Kingdom / British Heart Foundation / / PG/05/082
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / RASSF1 protein, mouse; 0 / Tumor Suppressor Proteins; 0 / Vasoconstrictor Agents; 1WS297W6MV / Phenylephrine; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


23. Kastellanos SS, Toumpoulis IK, Aggeli C, Zezas S, Chlapoutakis E, Kastellanos S, Stefanadis CI: The role of sex and biochemical markers of inflammation in left ventricular remodelling, before and after surgery, in elderly patients with aortic valve stenosis. Hellenic J Cardiol; 2009 Jan-Feb;50(1):26-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of sex and biochemical markers of inflammation in left ventricular remodelling, before and after surgery, in elderly patients with aortic valve stenosis.
  • INTRODUCTION: The aim of this study was to determine whether sex and biochemical markers of inflammation have a role in left ventricular (LV) remodelling after aortic valve replacement in elderly patients with aortic valve stenosis.
  • METHODS: We studied 52 elderly patients with aortic valve stenosis (32 men, mean age 65 +/- 11 years and 20 women, mean age 68 +/- 9 years).
  • Body surface area did not differ between men and women (1.81 +/- 0.15 versus 1.84 +/- 0.20, respectively).
  • All patients underwent a complete echocardiographic examination for the determination of ejection fraction (EF), LV mass and mass index, peak and mean systolic pressure gradient, aortic valve area, early (E) and late (A) transmitral flow wave velocities and their ratio (E/A), tissue Doppler indexes of the mitral annulus (Sa, Ea, Aa), and the E/Ea ratio.
  • In addition, levels of high sensitivity C-reactive protein (hsCRP), tumour necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1) were measured from venous blood samples taken before, and 10 days, 3 months and 6 months after aortic valve replacement.
  • RESULTS: LV mass decreased from 297 +/- 99.7 g before aortic valve replacement to 210 +/- 67 g 3 months after surgery and to 210 +/- 74 g 6 months after surgery (p<0.001).
  • Peak and mean systolic pressure gradients decreased, whereas aortic valve area increased after valve replacement (p<0.001).
  • The long-term changes in peak and mean pressure gradients, aortic valve area and LV mass after aortic valve replacement were well correlated with the long-term changes in hsCRP, TNF-alpha and MCP-1 in both men and women.
  • CONCLUSIONS: LV remodelling is similar in elderly men and women with aortic valve disease who have similar body surface area.
  • Although inflammatory markers are not correlated with echocardiographic parameters before aortic valve replacement, a strong correlation exists after operation.
  • [MeSH-major] Aortic Valve Stenosis / complications. Aortic Valve Stenosis / surgery. C-Reactive Protein / metabolism. Chemokine CCL2 / blood. Tumor Necrosis Factor-alpha / blood. Ventricular Remodeling / physiology

  • Genetic Alliance. consumer health - Aortic Valve Stenosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196618.001).
  • [ISSN] 1109-9666
  • [Journal-full-title] Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē
  • [ISO-abbreviation] Hellenic J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


24. Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, Zheng S, Wang A, Zhang C, Chen L, Lei N: Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro. Cancer Biol Ther; 2009 Aug;8(15):1489-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vitro.
  • Additionally, VEGF-induced vessel sprouting of rat aortic ring was also inhibited by HS.
  • In vivo, a tumor growth inhibition study was carried out using mice bearing B16F10 cells model of metastasis, no matter experimental or spontaneous, showed that HS at 5.2, 11.6 and 26 mg/kg (weight of mice) could markedly decreased the metastatic tumors in mouse lung in a dose-dependent manner.
  • In CAM assay and Matrigel plug assay in vivo, HS (50 microg/egg and 100 microg/egg) inhibited new blood vessel formation on the growing chick chorioallantoic membrane, and HS (5.2 and 26 mg/kg body weight) reduced the vessel density in Matrigel plugs implanted in mice.
  • [MeSH-major] Angiogenesis Inhibitors / isolation & purification. Antineoplastic Agents / pharmacology. Glycosaminoglycans / pharmacology. Holothuria / chemistry. Melanoma, Experimental / drug therapy. Neoplasm Invasiveness / prevention & control
  • [MeSH-minor] Animals. Aorta / drug effects. Cell Line / cytology. Cell Line / drug effects. Cell Line, Tumor / cytology. Cell Line, Tumor / drug effects. Cell Movement / drug effects. Drug Screening Assays, Antitumor. Endothelial Cells / cytology. Endothelial Cells / drug effects. Humans. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Mice. Mice, Inbred C57BL. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Rats. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483477.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Glycosaminoglycans; 0 / Neoplasm Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


25. Seo S, Miki A, Kitai T, Ino K, Higashiyama H, Ukikusa M: [A case of gastric cancer with abdominal para-aortic lymph node metastases responding to TS-1 + CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1171-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with abdominal para-aortic lymph node metastases responding to TS-1 + CDDP neoadjuvant chemotherapy].
  • A CT scan of the abdomen showed enlargement of many huge abdominal para-aortic lymph nodes.
  • Combined chemotherapy of TS-1 and CDDP was planned in order to reduce the tumor.
  • TS-1 (100 mg/body/day) was administered for 21 days followed by 14 days rest as one course.
  • CDDP (96 mg/body) was administered 8 days after the start of TS-1.
  • Neoadjuvant chemotherapy with TS-1 and CDDP is so effective that can it be adapted for advanced gastric cancer with para-aortic lymph node enlargement for downstaging.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121923.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Miyagi T, Nagasaki A, Shinzato O, Ohshima K, Takasu N: [Interdigitating dendritic cell sarcoma/tumor--a case report]. Gan To Kagaku Ryoho; 2007 Mar;34(3):469-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma/tumor--a case report].
  • We report an extremely rare case of interdigitating dendritic cell sarcoma/tumor (IDCS).
  • Whole-body computerized tomography showed enlarged lymph nodes in mediastinal, right axillary, abdominal para-aortic, ileum, and inguinal regions.
  • Immunohistochemically, the tumor cells expressed S-100 protein, CD 68, and CD 45 RO.
  • These findings were compatible with the diagnosis of IDCS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353646.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


27. Shavelle DM, Katz R, Takasu J, Lima JA, Jenny NS, Budoff MJ, O'Brien KD: Soluble intercellular adhesion molecule-1 (sICAM-1) and aortic valve calcification in the multi-ethnic study of atherosclerosis (MESA). J Heart Valve Dis; 2008 Jul;17(4):388-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble intercellular adhesion molecule-1 (sICAM-1) and aortic valve calcification in the multi-ethnic study of atherosclerosis (MESA).
  • BACKGROUND AND AIM OF THE STUDY: Previous studies have reported associations between individual inflammatory biomarkers and aortic valve disease, but none has examined associations with, baseline prevalence or severity of aortic valve calcium (AVC), as measured with cardiac computed tomography (CT).
  • METHODS: The associations of inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen, D-dimer, soluble intercellular adhesion molecule-1 (sICAM-1), heat shock protein 60 (Hsp60), soluble tumor necrosis factor receptor-1 (sTNF-R1), soluble tissue factor (sTF), soluble E-selectin and matrix metalloproteinases-3 and -9 (MMP-3 and -9) with baseline AVC prevalence and severity were examined.
  • RESULTS: After adjusting for age, gender, race and cardiovascular risk factors (smoking, hypertension, diabetes, total cholesterol, HDL, serum creatinine, body mass index and lipid-lowering therapy), the point prevalence ratios (95% confidence interval) for prevalent AVC were 1.20 (1.04,1.39) for sICAM-1,1.13 (1.03, 1.24) for IL-6, and 1.11 (1.02, 1.21) for D-dimer.
  • [MeSH-major] Aortic Valve Stenosis / blood. Atherosclerosis / blood. Biomarkers / blood. Calcinosis / blood. Intercellular Adhesion Molecule-1 / blood


28. Sallam N, Khazaei M, Laher I: Effect of moderate-intensity exercise on plasma C-reactive protein and aortic endothelial function in type 2 diabetic mice. Mediators Inflamm; 2010;2010:149678
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of moderate-intensity exercise on plasma C-reactive protein and aortic endothelial function in type 2 diabetic mice.
  • The aim of this study was to evaluate the effects of moderate-intensity exercise on plasma levels of C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-α) as markers of low-grade inflammation and endothelial function in diabetic (db/db) mice.
  • Aortic endothelial function was evaluated after two- and six-week exercises using a wire myograph.
  • After two weeks of exercise, aortic endothelial function was significantly improved without affecting body weight or plasma CRP levels.
  • Six weeks of exercise not only improved endothelial function, but also significantly reduced body weight and plasma CRP levels in db/db mice.
  • [MeSH-minor] Animals. Body Weight / physiology. Citrate (si)-Synthase / metabolism. Mice. Random Allocation

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci (Lond). 2005 Feb;108(2):121-8 [15504106.001]
  • [Cites] Herz. 2004 Dec;29(8):741-8 [15599670.001]
  • [Cites] Diabet Med. 2005 Aug;22(8):999-1004 [16026364.001]
  • [Cites] JAMA. 1999 Dec 8;282(22):2131-5 [10591334.001]
  • [Cites] Diabetologia. 2000 Jan;43(1):83-90 [10663220.001]
  • [Cites] Circulation. 2000 Apr 18;101(15):1780-4 [10769277.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):36-52 [11159815.001]
  • [Cites] JAMA. 2001 Sep 12;286(10):1218-27 [11559268.001]
  • [Cites] Clin Chim Acta. 2002 Mar;317(1-2):1-15 [11814453.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):393-403 [11832527.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):793-801 [11893790.001]
  • [Cites] Circulation. 2002 Aug 20;106(8):913-9 [12186793.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1042-7 [12714437.001]
  • [Cites] Am J Cardiol. 2003 Sep 1;92(5):522-8 [12943870.001]
  • [Cites] Circulation. 2003 Nov 11;108(19):2317-22 [14568895.001]
  • [Cites] J Appl Physiol (1985). 2004 Apr;96(4):1425-32 [14672961.001]
  • [Cites] Endocrinology. 2004 May;145(5):2273-82 [14726444.001]
  • [Cites] Diabetes. 1974 Feb;23(2):105-11 [4359625.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):538-45 [8426621.001]
  • [Cites] Endocr Rev. 1995 Apr;16(2):164-76 [7781592.001]
  • [Cites] BMJ. 1996 Mar 23;312(7033):744-5 [8605460.001]
  • [Cites] Diabetes Care. 1998 Feb;21(2):271-7 [9539995.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] Diabetologia. 1999 Mar;42(3):351-7 [10096789.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1649-52 [10335783.001]
  • [Cites] Diabetes Care. 1999 Jun;22(6):973-81 [10372251.001]
  • [Cites] Diabet Med. 2005 Sep;22(9):1212-7 [16108851.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2005 Jan;2(1):29-36; quiz 58 [16265340.001]
  • [Cites] Clin Sci (Lond). 2007 Jun;112(7):375-84 [17324119.001]
  • [Cites] Med Sci Monit. 2007 Aug;13(8):BR168-74 [17660720.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 May;49(5):2053-60 [18436840.001]
  • [Cites] Ann Acad Med Singapore. 2008 Apr;37(4):286-93 [18461212.001]
  • [Cites] Diabetologia. 2008 Jul;51(7):1327-37 [18437348.001]
  • [Cites] Glycoconj J. 2008 Aug;25(6):573-9 [18347976.001]
  • [Cites] Clin J Sport Med. 2008 Sep;18(5):423-31 [18806550.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1470-80 [18641279.001]
  • [Cites] Physiol Res. 2008;57(6):847-56 [18052681.001]
  • [Cites] Am J Physiol Renal Physiol. 2009 Apr;296(4):F700-8 [19144689.001]
  • [Cites] Eur J Appl Physiol. 2009 Jul;106(5):721-9 [19430945.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 Dec;38(6):689-96 [19775917.001]
  • [Cites] Atherosclerosis. 2010 Apr;209(2):601-5 [19954777.001]
  • [Cites] J Strength Cond Res. 2010 May;24(5):1389-98 [20386477.001]
  • [Cites] Int J Sports Med. 2010 Jul;31(7):441-50 [20432196.001]
  • [Cites] Diabetes. 1999 Sep;48(9):1856-62 [10480619.001]
  • [Cites] CMAJ. 2005 Apr 26;172(9):1199-209 [15851714.001]
  • (PMID = 20847810.001).
  • [ISSN] 1466-1861
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein; EC 2.3.3.1 / Citrate (si)-Synthase
  • [Other-IDs] NLM/ PMC2929502
  •  go-up   go-down


29. Takahashi S, Yoshida K, Mikami S, Oya M, Kawase T: Development of testicular alpha-fetoprotein-secreting germ cell tumor 3 years after treatment of intracranial lesion identified as non-secreting germ cell tumor on the basis of clinical data--case report. Neurol Med Chir (Tokyo); 2008;48(11):522-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of testicular alpha-fetoprotein-secreting germ cell tumor 3 years after treatment of intracranial lesion identified as non-secreting germ cell tumor on the basis of clinical data--case report.
  • A 22-year-old Asian male developed testicular alpha-fetoprotein (AFP)-secreting germ cell tumor 3 years after treatment of a disseminated intracranial lesion identified as non-secreting germ cell tumor on the basis of clinical data.
  • The blood AFP level was as high as 129 ng/ml (previously, as low as 5 ng/ml) and abdominal computed tomography showed para-aortic lymph node swelling.
  • Left orchidectomy was performed and histological examination indicated the presence of AFP-secreting germ cell tumor despite severe necrosis of the tissue.
  • Improved chemoradiotherapy for intracranial germ cell tumor will lead to long-term survival of most patients with germ cell tumor.
  • Patients may subsequently develop germ cell tumors at other sites in the body.
  • Therefore, follow up should monitor for tumor recurrence not only in the brain but also in other locations.
  • [MeSH-major] Neoplasm Proteins / analysis. Neoplasms, Germ Cell and Embryonal / secondary. Supratentorial Neoplasms / pathology. Testicular Neoplasms / secondary. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029782.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  • [Number-of-references] 12
  •  go-up   go-down


30. Huang H, Tang QZ, Wang AB, Chen M, Yan L, Liu C, Jiang H, Yang Q, Bian ZY, Bai X, Zhu LH, Wang L, Li H: Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension; 2010 Aug;56(2):232-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling.
  • A20 or tumor necrosis factor-induced protein 3 is a negative regulator of nuclear factor kappaB signaling.
  • Cardiac hypertrophy was produced by aortic banding in A20 transgenic mice and control animals.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci (Lond). 2008 Oct;115(7):203-18 [18752467.001]
  • [Cites] Immunity. 2008 Mar;28(3):381-90 [18342009.001]
  • [Cites] Hypertension. 2008 Dec;52(6):1060-7 [18981328.001]
  • [Cites] J Mol Med (Berl). 2009 Mar;87(3):249-60 [19096818.001]
  • [Cites] Hypertension. 2009 Mar;53(3):539-48 [19204184.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:3168-87 [19273265.001]
  • [Cites] J Biol Chem. 2009 Mar 27;284(13):8217-21 [19008218.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):977-80 [19380636.001]
  • [Cites] EMBO J. 2009 Jul 22;28(14):2028-41 [19536134.001]
  • [Cites] Trends Immunol. 2009 Aug;30(8):383-91 [19643665.001]
  • [Cites] Hypertension. 2008 Nov;52(5):910-7 [18824663.001]
  • [Cites] Cardiovasc Res. 2004 Aug 15;63(3):467-75 [15276472.001]
  • [Cites] Nat Med. 2000 May;6(5):556-63 [10802712.001]
  • [Cites] Circulation. 2001 Feb 6;103(5):670-7 [11156878.001]
  • [Cites] J Am Coll Cardiol. 2003 May 7;41(9):1606-10 [12742304.001]
  • [Cites] Circulation. 2003 Aug 12;108(6):664-7 [12900338.001]
  • [Cites] J Mol Cell Cardiol. 2003 Dec;35(12):1385-94 [14654364.001]
  • [Cites] Trends Cardiovasc Med. 2004 Feb;14(2):50-5 [15030789.001]
  • [Cites] Cardiovasc Res. 2004 Aug 15;63(3):423-32 [15276467.001]
  • [Cites] J Mol Cell Cardiol. 2004 Sep;37(3):705-15 [15350844.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 15;38(2):243-57 [15607907.001]
  • [Cites] J Mol Cell Cardiol. 2005 Jan;38(1):47-62 [15623421.001]
  • [Cites] Trends Biochem Sci. 2005 Jan;30(1):1-4 [15653317.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):527-37 [15765134.001]
  • [Cites] Cardiovasc Res. 2006 Mar 1;69(4):888-98 [16375879.001]
  • [Cites] J Cell Physiol. 2006 Aug;208(2):307-18 [16646083.001]
  • [Cites] Free Radic Biol Med. 2006 May 15;40(10):1756-75 [16767845.001]
  • [Cites] Circ Res. 2006 Nov 24;99(11):1233-42 [17068291.001]
  • [Cites] Circ Res. 2006 Dec 8;99(12):1315-28 [17158347.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2852-5 [17218788.001]
  • [Cites] Circulation. 2007 Apr 10;115(14):1885-94 [17389268.001]
  • [Cites] Hypertension. 2007 Jun;49(6):1399-408 [17420335.001]
  • [Cites] J Biomed Sci. 2007 May;14(3):357-71 [17260188.001]
  • [Cites] Circulation. 2007 Sep 18;116(12):1413-23 [17875982.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2008 Mar;35(3):335-41 [18290874.001]
  • [ErratumIn] Hypertension. 2010 Sep;56(3):e40
  • (PMID = 20585109.001).
  • [ISSN] 1524-4563
  • [Journal-full-title] Hypertension (Dallas, Tex. : 1979)
  • [ISO-abbreviation] Hypertension
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL084456-06; United States / NHLBI NIH HHS / HL / R01 HL085499-02; United States / NHLBI NIH HHS / HL / HL084456-04W1; United States / NHLBI NIH HHS / HL / R01 HL084456-03; United States / NHLBI NIH HHS / HL / R01 HL084456-04W1; United States / NHLBI NIH HHS / HL / HL085499-02; United States / NHLBI NIH HHS / HL / HL085499-05; United States / NHLBI NIH HHS / HL / HL084456-05; United States / NHLBI NIH HHS / HL / R01 HL085499-03; United States / NHLBI NIH HHS / HL / HL085499-01; United States / NHLBI NIH HHS / HL / HL085499-03; United States / NHLBI NIH HHS / HL / R01 HL084456-02; United States / NHLBI NIH HHS / HL / HL085499-04; United States / NHLBI NIH HHS / HL / HL084456-03; United States / NHLBI NIH HHS / HL / R01 HL085499-03W1; United States / NHLBI NIH HHS / HL / R01 HL085499-05; United States / NHLBI NIH HHS / HL / R01 HL084456-04; United States / NHLBI NIH HHS / HL / HL084456-06; United States / NHLBI NIH HHS / HL / R01 HL084456-05; United States / NHLBI NIH HHS / HL / HL084456-02; United States / NHLBI NIH HHS / HL / R01 HL085499; United States / NHLBI NIH HHS / HL / R01 HL085499-04; United States / NHLBI NIH HHS / HL / HL084456-04; United States / NHLBI NIH HHS / HL / R01 HL084456; United States / NHLBI NIH HHS / HL / R01 HL085499-01; United States / NHLBI NIH HHS / HL / HL085499-03W1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Transforming Growth Factor beta1; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP kinase kinase kinase 7; EC 6.3.2.19 / TNFAIP3 protein, human
  • [Other-IDs] NLM/ NIHMS255077; NLM/ PMC3046919
  •  go-up   go-down


31. Galisteo M, Sánchez M, Vera R, González M, Anguera A, Duarte J, Zarzuelo A: A diet supplemented with husks of Plantago ovata reduces the development of endothelial dysfunction, hypertension, and obesity by affecting adiponectin and TNF-alpha in obese Zucker rats. J Nutr; 2005 Oct;135(10):2399-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to analyze whether consumption of a fiber-supplemented diet containing 3.5% Plantago ovata husks prevented many of the abnormalities clustered in the metabolic syndrome, including obesity, dyslipidemia, hypertension and endothelial dysfunction.
  • Body weights were measured weekly.
  • At the end of the treatment, plasma concentrations of triglycerides, total cholesterol, FFAs, glucose, insulin, adiponectin, and tumor necrosis factor alpha (TNF-alpha) were determined, and studies on vascular function were performed using aortic rings.
  • Rats fed the P. ovata husk-supplemented diet had a significantly reduced body weight gain compared with those fed the standard diet.
  • Decreased endothelium-dependent relaxation in response to acetylcholine (ACh) by aortic rings from obese Zucker rats was improved in those fed the fiber-supplemented diet.
  • We conclude that intake of a P. ovata husk-supplemented diet prevents endothelial dysfunction, hypertension, and obesity development, and ameliorates dyslipidemia and abnormal plasma concentrations of adiponectin and TNF-alpha in obese Zucker rats.
  • [MeSH-major] Adiponectin / blood. Hypertension / diet therapy. Metabolic Syndrome X / diet therapy. Obesity / diet therapy. Plantago. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177203.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Lipids; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


32. Zhao H, Liao Y, Minamino T, Asano Y, Asakura M, Kim J, Asanuma H, Takashima S, Hori M, Kitakaze M: Inhibition of cardiac remodeling by pravastatin is associated with amelioration of endoplasmic reticulum stress. Hypertens Res; 2008 Oct;31(10):1977-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to investigate whether pravastatin can inhibit cardiac remodeling and ameliorate endoplasmic reticulum (ER) stress caused by pressure overload or tumor necrosis factor alpha (TNFalpha).
  • Either pravastatin (5 mg/kg/d) or vehicle alone was orally administered to male C57BL/6J mice from day 2 after a transverse aortic constriction (TAC) was performed.
  • Four weeks after TAC, pravastatin treatment significantly reduced heart/body weight and lung/body weight ratios and increased left ventricular (LV) fractional shortening compared with the TAC alone.
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cardiomegaly / drug therapy. Cardiomegaly / metabolism. Cardiomegaly / pathology. Fibrosis. Lipopolysaccharides / pharmacology. Male. Mice. Mice, Inbred C57BL. Molecular Chaperones / metabolism. Myocardium / metabolism. Myocardium / pathology. Myocytes, Cardiac / metabolism. Myocytes, Cardiac / pathology. Signal Transduction / drug effects. Tumor Necrosis Factor-alpha / metabolism. Ventricular Pressure

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015605.001).
  • [ISSN] 0916-9636
  • [Journal-full-title] Hypertension research : official journal of the Japanese Society of Hypertension
  • [ISO-abbreviation] Hypertens. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Lipopolysaccharides; 0 / Molecular Chaperones; 0 / Tumor Necrosis Factor-alpha; KXO2KT9N0G / Pravastatin
  •  go-up   go-down


33. Fakhry N, Niccoli-Sire P, Barlier-Seti A, Giorgi R, Giovanni A, Zanaret M: Cervical paragangliomas: is SDH genetic analysis systematically required? Eur Arch Otorhinolaryngol; 2008 May;265(5):557-63
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 29 patients operated on cervical paragangliomas (carotid or vagal body) at our institution between 1994 and 2007, 23 could be asked for a genetic analysis and a familial study.
  • In patients presenting with a mutation, 50% had a family history of paraganglioma compared with 0% for others (P = 0.008) and 87.5% had a multifocal form of paragangliomas versus 0% for others (P = 0.001).
  • In the 16 patients who had an apparently sporadic paraganglioma, 6% had mutations in the SDH gene.
  • A positive family history of paraganglioma and/or the presence of bilateral or multiple paragangliomas and/or an early age of onset are the main parameters associated with SDH mutations.
  • Genetic testing should be considered for all patients with a cervical paraganglioma, even for those presenting with an apparently sporadic tumor as familial form may be such identified in 6% of cases.
  • [MeSH-major] Genetic Testing / utilization. Germ-Line Mutation. Head and Neck Neoplasms / genetics. Paraganglioma, Extra-Adrenal / genetics. Succinate Dehydrogenase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aortic Bodies / pathology. Carotid Body Tumor / genetics. Female. Humans. Male. Membrane Proteins / genetics. Middle Aged

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987308.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / SDHC protein, human; 0 / SDHD protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


34. du Toit EF, Nabben M, Lochner A: A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/reperfusion injury. Basic Res Cardiol; 2005 Jul;100(4):346-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Obesity was associated with elevated serum angiotensin II (0.050 +/- 0.015 pmol/ml vs. 0.035 +/- 0.003 pmol/ml, p < 0.05) and TNFalpha levels (42.8 +/- 5.93 pg/ml vs. 13.18 +/- 2.50 pg/ml, p < 0.05), and increased heart to body weight ratios (3.1 +/- 0.04 mg/g vs. 2.8 +/- 0.03 mg/g, p < 0.05).
  • Losartan had no effect on body weight but decreased basal myocardial angiotensin II and TNFAlpha levels as well as heart to body weight ratio in the obese and lean controls (2.5 +/- 0.05 mg/g and 2.6 +/- 0.04 mg/g relative to their controls, p < 0.05).
  • Hearts from obese rats had lower reperfusion aortic outputs (AO) than their concurrent controls (18.42 +/- 1.17 ml/min vs. 27.8 +/- 0.83 ml/min, p < 0.05).
  • Losartan improved aortic output recoveries in obese rats (23.0 +/- 1.71 ml/min, p < 0.05).
  • CONCLUSIONS: Obesity increased serum angiotensin II and TNFalpha levels, blood pressure, and heart weight to body weight ratios.
  • [MeSH-minor] Animals. Blood Glucose / analysis. Cardiac Output. Male. Myocardial Ischemia / metabolism. Myocardium / chemistry. Rats. Rats, Wistar. Tumor Necrosis Factor-alpha / analysis. Ventricular Remodeling

  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821998.001).
  • [ISSN] 0300-8428
  • [Journal-full-title] Basic research in cardiology
  • [ISO-abbreviation] Basic Res. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Tumor Necrosis Factor-alpha; 11128-99-7 / Angiotensin II
  •  go-up   go-down


35. Lv S, Fan R, Du Y, Hou M, Tang Z, Ling W, Zhu H: Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice. Eur J Nutr; 2009 Jun;48(4):205-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atherosclerotic lesion area in the aortic sinus, levels of tumor necrosis factor (TNF)-alpha and monocyte chemoattractant protein (MCP)-1 in aorta and serum, serum lipids, and methylation status of TNF-alpha promoter in aorta were determined.
  • Betaine supplementation also reduced aortic expression of TNF-alpha in a dose-dependent way in four groups of apoE-deficient mice, and Pearson correlation revealed that atherosclerotic lesion area was positively associated with aortic TNF-alpha level (r = 0.777, P < 0.001).
  • In this study, apoE-deficient mice receiving betaine supplementation for 14 weeks had higher concentrations of serum total cholesterol (P < 0.01), LDL cholesterol (P < 0.05), and lower body weight (P < 0.05) than no-betaine mice.
  • CONCLUSIONS: These data suggest that despite exacerbating hyperlipidemia in apoE-deficient mice, betaine may exert its anti-atherogenic effect by inhibiting aortic inflammatory response mediated by TNF-alpha.
  • [MeSH-major] Apolipoproteins E / deficiency. Atherosclerosis / pathology. Betaine / pharmacology. Chemokine CCL2 / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. BETAINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19255798.001).
  • [ISSN] 1436-6215
  • [Journal-full-title] European journal of nutrition
  • [ISO-abbreviation] Eur J Nutr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Chemokine CCL2; 0 / Inflammation Mediators; 0 / Lipids; 0 / Tumor Necrosis Factor-alpha; 3SCV180C9W / Betaine
  •  go-up   go-down


36. Yanaga Y, Awai K, Nakayama Y, Nakaura T, Tamura Y, Funama Y, Aoyama M, Asada N, Yamashita Y: Optimal dose and injection duration (injection rate) of contrast material for depiction of hypervascular hepatocellular carcinomas by multidetector CT. Radiat Med; 2007 Jul;25(6):278-88
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During a 33-s period, patients with a body weight < or =50 kg received 100 ml of non-ionic CM with an iodine concentration of 300 mg I/ml; patients whose body weight was >50 kg received 100 ml of CM with an iodine concentration of 370 mg I/ml.
  • First, we measured enhancement in the abdominal aorta and tumor-to-liver contrast (TLC) during the EAP and LAP.
  • Next, to investigate the relation between aortic enhancement and TLC during the LAP, two radiologists visually assessed the conspicuity of hypervascular HCCs during the LAP using a 3-point scale: grade 1, poor; grade 2, fair; grade 3, excellent.
  • Finally, to examine the effect of the CM dose and injection duration on aortic enhancement during the EAP, we simulated aortic enhancement curves using test bolus data obtained for 10 HCC patients and the method of Fleischmann and Hittmair.
  • RESULTS: A relatively strong correlation was observed between aortic enhancement during the EAP and TLC during the LAP (correlation coefficient r = 0.75, P < 0.001).
  • The 95% confidence intervals for the population mean for aortic enhancement during EAP in patients with tumor conspicuity grades of 1, 2, and 3 were 188.5, 222.4; 228.8, 259.3; and 280.2, 322.5 HU (Hounsfield Unit), respectively.
  • Thus, we considered the lower limit of the aortic enhancement value for excellent depiction of HCCs during EAP to be 280 HU.
  • To achieve an aortic enhancement value of >280 HU for aortic enhancement simulations during EAP, the injection duration should be <25 s for patients receiving a CM dose of 1.7 ml/kg with 300 mg I/ml iodine and <30 s for those receiving 2.0 ml/kg.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634881.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


37. Meriggi F, Gramigna P, Forni E: Extended lymphadenectomy in cephalic pancreatoduodenectomy. Personal observations. Hepatogastroenterology; 2007 Mar;54(74):549-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: At the General Surgical Clinic of Pavia University 20 patients (14 men, 6 women, mean age 62.4 yr) with pancreatic head cancer (17 adenocarcinoma, 1 lymphoma, 2 carcinoma) underwent Whipple's exeresis with a regional (peripancreatic or R1) and juxta-regional (para-aortic or R2) lymphadenectomy according to the Ishikawa technique, between 1996-2000.
  • R2 nodes consisted of lymph nodes at the superior and inferior pancreatic body, mid colic region, common hepatic duct, celiac axis and para-aortic region.
  • Tumor diameter was less than 4cm in 83.3% of cases.
  • CONCLUSIONS: An earlier diagnosis (with tumor diameter <4 cm) can improve pancreatic head cancer prognosis.
  • [MeSH-minor] Adult. Aged. Cholestasis, Extrahepatic / mortality. Cholestasis, Extrahepatic / pathology. Cholestasis, Extrahepatic / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / etiology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523320.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


38. Korff T, Dandekar G, Pfaff D, Füller T, Goettsch W, Morawietz H, Schaffner F, Augustin HG: Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31. Arterioscler Thromb Vasc Biol; 2006 Mar;26(3):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Arteriovenous asymmetrical endothelial cell ephrinB2 expression in vivo is lost on transfer into culture with aortic endothelial cells becoming partially ephrinB2-negative and saphenous vein endothelial cells becoming partially ephrinB2-positive.
  • In contrast, monolayer endothelial cells translocate ephrinB2 to interendothelial cell junctions, which is strongly enhanced by EphB4-Fc-mediated receptor body activation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357318.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Ephrin-B2; 0 / Ligands; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


39. Mingorance C, de Sotomayor MA, Marhuenda E, Herrera MD: Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats. J Cardiovasc Pharmacol; 2010 Nov;56(5):560-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the effect of chronic cannabinoid 1 antagonism on vascular prostanoid production, obese Zucker rats were treated with rimonabant (10 mg/kg per day) during 20 weeks and then vascular and endothelial reactivity were assessed in aortic rings by analyzing response to phenylephrine and acetylcholine.
  • The presence of cyclo-oxygenase-1 and cyclo-oxygenase-2 selective inhibitors (SC-560 and NS-398, respectively) and the enzyme immunoassay revealed lower PGI2 production by aortic rings from obese rats with rimonabant able to restore such response toward levels found in the lean animals.
  • Finally, rimonabant was also able to reduce tumor necrosis factor-α produced by adipose tissue of obese Zucker rats.
  • [MeSH-minor] Acetylcholine / pharmacology. Animals. Aorta, Thoracic / drug effects. Aorta, Thoracic / metabolism. Aorta, Thoracic / physiopathology. Body Weight / drug effects. Endothelium, Vascular / drug effects. Endothelium, Vascular / enzymology. Endothelium, Vascular / metabolism. Nitric Oxide Synthase Type II / metabolism. Nitrobenzenes / pharmacology. Phenylephrine / pharmacology. Rats. Rats, Zucker. Sulfonamides / pharmacology. Tumor Necrosis Factor-alpha / metabolism. Vasodilator Agents / pharmacology

  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729749.001).
  • [ISSN] 1533-4023
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrobenzenes; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 0 / SC 560; 0 / Sulfonamides; 0 / Tumor Necrosis Factor-alpha; 0 / Vasodilator Agents; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 158681-13-1 / rimonabant; 1WS297W6MV / Phenylephrine; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


40. Freeling J, Wattier K, LaCroix C, Li YF: Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload. Exp Physiol; 2008 Jan;93(1):75-82
Hazardous Substances Data Bank. PILOCARPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload.
  • The inflammatory cytokine tumour necrosis factor alpha (TNF alpha) is known to be a major factor contributing to cardiac remodelling and dysfunction.
  • In the present study, we tested the effects of a cholinesterase inhibitor, neostigmine, and a muscarinic cholinergic agonist, pilocarpine, on cardiac hypertrophy and TNF alpha levels during pressure overload.
  • Rats with transverse aortic constriction exhibited elevated TNF alpha protein levels in the heart, increased heart weight to body weight ratios (an index of cardiac hypertrophy) and decreased left ventricular diastolic function.
  • Two weeks of infusion with neostigmine (6 microg kg(-1) day(-1)) or pilocarpine (0.3 mg kg(-1) day(-1)) significantly reduced cardiac hypertrophy, reduced TNF alpha levels and elevated interleukin-10 levels in heart tissues, and improved ventricular function in rats with transverse aortic constriction.
  • [MeSH-major] Cardiomegaly / prevention & control. Heart / physiology. Neostigmine / pharmacology. Parasympathomimetics / pharmacology. Pilocarpine / pharmacology. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / biosynthesis
  • [MeSH-minor] Animals. Animals, Newborn. Body Weight / physiology. Cells, Cultured. Constriction, Pathologic / physiopathology. Drug Interactions. Enzyme-Linked Immunosorbent Assay. Interleukin-10 / biosynthesis. Male. Organ Size / physiology. Phenylephrine / pharmacology. Pressure. Rats. Rats, Sprague-Dawley. Sympathomimetics / pharmacology. Ventricular Function

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • Hazardous Substances Data Bank. NEOSTIGMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17872965.001).
  • [ISSN] 0958-0670
  • [Journal-full-title] Experimental physiology
  • [ISO-abbreviation] Exp. Physiol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 2 P20 RR016479; United States / NCRR NIH HHS / RR / 5 P20 RR017662
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parasympathomimetics; 0 / Sympathomimetics; 0 / Tumor Necrosis Factor-alpha; 01MI4Q9DI3 / Pilocarpine; 130068-27-8 / Interleukin-10; 1WS297W6MV / Phenylephrine; 3982TWQ96G / Neostigmine
  •  go-up   go-down


41. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K: [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases]. Hinyokika Kiyo; 2007 Jul;53(7):489-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1 was a 76-year-old man with loss of appetite and body weight and neck lymphadenopathies.
  • Whole body computed tomography (CT) revealed prostatic swelling, pancreatic mass, para-aortic lymphadenopathies, and multiple lung nodules.
  • Elevation of tumor markers (prostate specific antigen [PSA, 1,760 ng/ml] and neuron-specific enolase [NSE, 88 ng/ml]) was noted.
  • The patient died three months after the diagnosis.
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male. Phosphopyruvate Hydratase / blood. Prostate-Specific Antigen / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17702184.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


42. Chastan M, Manrique A, Baron M, Sanson AE, Diologent B, Vera P, Hitzel A: [Prognostic value of pretherapeutic 18F-FDG PET/CT in cancer of the uterine cervix: a retrospective study of 53 patients]. Gynecol Obstet Fertil; 2010 Apr;38(4):244-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each patient has been evaluated with pretherapeutic whole-body FDG PET/CT and pelvic MRI.
  • On PET/CT, we have visually analyzed metabolism of primary tumor, pelvic and para-aortic lymph nodes in comparison with surrounding structures.
  • RESULTS: Para-aortic lymph node abnormal uptake on PET/CT was the only independent predictor of progression-free survival.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier SAS.
  • (PMID = 20359931.001).
  • [ISSN] 1769-6682
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


43. Evans JM, Collins M: Clinically diagnosed glomus vagale tumour treated with external beam radiotherapy: a review of the published reports. J Med Imaging Radiat Oncol; 2008 Dec;52(6):617-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinically diagnosed glomus vagale tumour treated with external beam radiotherapy: a review of the published reports.
  • The aim of the study was to present a case of clinically diagnosed glomus vagale in a 42-year-old Aboriginal woman treated with external beam radiotherapy and to carry out a review of the published work.
  • The details of presentation, diagnosis, treatment and follow up of the patient are discussed.
  • A review of the published work was carry out using MEDLINE database with respect to aetiology, clinical presentation, diagnosis, treatment and expected outcomes.
  • Glomus vagale tumours are a subtype of paragangliomas of the head and neck derived from extra-adrenal paraganglia of the autonomic nervous system.
  • Glomus vagale tumours are rare and should be managed in a multidisciplinary head and neck clinic with both surgical and radiation oncology opinions offered.
  • [MeSH-major] Aortic Bodies / radiation effects. Carotid Body Tumor / diagnosis. Carotid Body Tumor / radiotherapy. Radiotherapy, Conformal / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178639.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 36
  •  go-up   go-down


44. Drucker AM, Houlden RL: A case of familial paraganglioma syndrome type 4 caused by a mutation in the SDHB gene. Nat Clin Pract Endocrinol Metab; 2006 Dec;2(12):702-6; quiz following 706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of familial paraganglioma syndrome type 4 caused by a mutation in the SDHB gene.
  • He had undergone resection of a paraganglioma superior to the right adrenal gland at 19 years of age, resection of two para-aortic paragangliomas at 39 years of age, and resection of a paraganglioma in the interatrial septum at 40 years.
  • The patient's mother had died at age 39 years of metastases from a carotid body tumor.
  • DIAGNOSIS: Familial paraganglioma syndrome type 4 caused by a mutation in the succinate dehydrogenase complex, subunit B gene.
  • The first was to remove two para-aortic paragangliomas, and the second to remove a paraganglioma that involved both atria.
  • If these procedures suggest a recurrence of paraganglioma, 123I-labeled metaiodobenzylguanidine scanning should be performed.
  • [MeSH-major] Iron-Sulfur Proteins / genetics. Paraganglioma, Extra-Adrenal / genetics. Succinate Dehydrogenase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143317.001).
  • [ISSN] 1745-8366
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron-Sulfur Proteins; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


45. Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL: Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice. Mol Cell Biochem; 2006 Apr;285(1-2):35-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LDLr deficient mice fed HF diet and simultaneously treated with fenofibrate (100 mg/kg body weight) prevented development of obesity, lowered serum triglycerides and cholesterol, improved insulin sensitivity, and prevented accumulation of lipids in the aorta.
  • The reductions in body weight were associated with elevation of hepatic uncoupling protein 2 (UCP2) mRNA, a concomitant increase in the ketone body formation, and improved insulin sensitivity associated with tumor necrosis factor-alpha reductions and phosphoenol pyruvate carboxykinase down-regulation.
  • Fenofibrate-mediated hypolipidemic effects together with improved insulin sensitivity and loss of adiposity led to the reductions in the aortic lipid deposition by inhibiting early stages of atherosclerosis possibly via vascular cell adhesion molecule-1 (VCAM-1) modulation.

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • Hazardous Substances Data Bank. Fenofibrate .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477380.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Insulin; 0 / Leptin; 0 / Ligands; 0 / Lipids; 0 / PPAR alpha; 0 / Receptors, LDL; 0 / Triglycerides; U202363UOS / Fenofibrate
  •  go-up   go-down


46. Hobbs RF, Baechler S, Wahl RL, He B, Song H, Esaias CE, Frey EC, Jacene H, Sgouros G: Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med; 2010 Mar;51(3):368-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In external-beam radiotherapy, these tumors present a challenge because imaging resolution prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall.
  • SPECT resolution is not sufficient to enable dosimetric analysis of anatomic features of the thickness of the aortic wall.
  • Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with (131)I-tositumomab.
  • Abdominal SPECT and whole-body planar images were obtained at 48, 72, and 144 h after tracer administration.
  • Tumor and blood activity concentrations, scaled to therapeutic administered activities-both standard and myeloablative-were input into a geometry and tracking model (GEANT, version 4) of the aorta.
  • The simulated energy deposited in the arterial walls was collected and fitted, and the AD and biologic effective dose values to the aortic wall and tumors were obtained for standard therapeutic and hypothetical myeloablative administered activities.
  • RESULTS: Arterial wall ADs from standard therapy were lower (0.6-3.7 Gy) than those typical from external-beam therapy, as were the tumor ADs (1.4-10.5 Gy).
  • The ratios of tumor AD to arterial wall AD were greater for radioimmunotherapy by a factor of 1.9-4.0.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2003 Mar;44(3):465-74 [12621016.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2351-7 [12750161.001]
  • [Cites] JAMA. 2003 Dec 3;290(21):2831-7 [14657067.001]
  • [Cites] Cardiovasc Radiat Med. 2003 Jul-Sep;4(3):146-51 [14984715.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Jun;19(3):363-70 [15285884.001]
  • [Cites] Am J Med. 1981 Mar;70(3):519-30 [6782873.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):181-90 [1993627.001]
  • [Cites] N Engl J Med. 1993 Oct 21;329(17):1219-24 [7692295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Nov 1;36(4):805-10 [8960506.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3270-8 [9779701.001]
  • [Cites] Radiat Oncol Investig. 1999;7(3):158-62 [10406057.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S [15653658.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S [15653661.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6508-15 [16170160.001]
  • [Cites] Phys Med Biol. 2005 Sep 7;50(17):4169-85 [16177538.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):718-25 [16353211.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):43-9 [17194904.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1396-402 [17312330.001]
  • [Cites] Kidney Int. 2007 Jun;71(11):1188 [17522700.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):1008-16 [17504874.001]
  • [Cites] Support Care Cancer. 2008 Apr;16(4):339-45 [18196290.001]
  • [Cites] Med Phys. 2008 Mar;35(3):1123-34 [18404947.001]
  • [Cites] J Nucl Med. 2008 May;49(5):837-44 [18413376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):848-57 [18514779.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jul;191(1):32-7 [18562721.001]
  • [Cites] J Nucl Med. 2008 Nov;49(11):1884-99 [18927342.001]
  • [Cites] Radiat Med. 2008 Dec;26(10):573-81 [19132487.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):163-5 [19171403.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1914-7 [19165857.001]
  • [Cites] Med Phys. 2009 Mar;36(3):904-7 [19378750.001]
  • [Cites] J Nucl Med. 2009 Nov;50(11):1844-7 [19837771.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1316-23 [10715303.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Feb;18(1):89-97 [12667312.001]
  • (PMID = 20150265.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116477-05; United States / NCI NIH HHS / CA / R01 CA116477; United States / NCI NIH HHS / CA / R01 CA116477-05; United States / NCI NIH HHS / CA / R01CA116477
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / iodine-131 anti-B1 antibody
  • [Other-IDs] NLM/ NIHMS246398; NLM/ PMC2967028
  •  go-up   go-down


47. Santillan A, Bristow RE: Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol; 2006 Feb;3(2):108-12; quiz 1 p following 112
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During her initial admission, the patient improved to some degree and was discharged with a possible diagnosis of viral meningitis.
  • INVESTIGATIONS: General physical and gynecological examinations, MRI of the brain, lumbar punctures, electroencephalogram, transvaginal ultrasound, mammogram, tumor markers, anti-neuronal antibodies, colonoscopy, whole-body positron emission tomography scan, laparoscopy and biopsies.
  • DIAGNOSIS: Stage IIIC endometrioid adenocarcinoma of the ovary with paraneoplastic cerebellar degeneration.
  • MANAGEMENT: Tumor cytoreduction, plasmapheresis, total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic and para-aortic lymph-node dissection, total omentectomy, carboplatin and paclitaxel chemotherapy, rehabilitation, and speech therapy.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Ovarian Neoplasms / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


48. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR: Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond); 2005 Mar;108(3):237-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore we measured serum OPG levels in patients with coronary artery disease, compared the serum OPG levels among the different groups according to the number of stenotic vessels and determined whether there was any correlation with aortic calcification, LV (left ventricular) mass index and serum CRP (C-reactive protein) levels.
  • Blood pressure, body mass index, fasting blood glucose, lipid profiles and CRP levels were measured and the LV mass indices were calculated using ECGs.
  • The presence of calcification in the aortic notch was checked by a chest X-ray.
  • There were no differences in serum OPG levels according to the presence of fasting hyperglycaemia or aortic calcification.
  • [MeSH-minor] Aged. Aortography. Biomarkers / blood. Calcinosis / blood. Calcinosis / complications. Calcinosis / radiography. Coronary Angiography. Disease Progression. Electrocardiography. Enzyme-Linked Immunosorbent Assay / methods. Humans. Middle Aged. Osteoprotegerin. Receptors, Tumor Necrosis Factor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15569000.001).
  • [ISSN] 0143-5221
  • [Journal-full-title] Clinical science (London, England : 1979)
  • [ISO-abbreviation] Clin. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glycoproteins; 0 / Osteoprotegerin; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11B protein, human; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


49. Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, Tang X, Ren Y, Tang C, Du J: Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol; 2009 Feb;29(2):173-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compared with control mice, apoE(-/-) mice showed decreased plasma H(2)S level and aortic H(2)S production but increased plasma ICAM-1 and aortic ICAM-1 protein and mRNA.
  • Compared with apoE(-/-) mice, apoE(-/-)+NaHS mice showed increased plasma H(2)S level, but decreased size of atherosclerotic plaque and plasma and aortic ICAM-1 levels, whereas apoE(-/-)+PPG mice showed decreased plasma H(2)S level but enlarged plaque size and increased plasma and aortic ICAM-1 levels.
  • NaHS suppressed ICAM-1 expression in tumor necrosis factor (TNF)-alpha-treated HUVECs.
  • [MeSH-minor] Active Transport, Cell Nucleus. Alkynes / pharmacology. Animals. Body Weight. Cells, Cultured. Cystathionine gamma-Lyase / antagonists & inhibitors. Cystathionine gamma-Lyase / genetics. Cystathionine gamma-Lyase / metabolism. Disease Models, Animal. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Foam Cells / drug effects. Foam Cells / metabolism. Glycine / analogs & derivatives. Glycine / pharmacology. Humans. I-kappa B Proteins / metabolism. Lipids / blood. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / metabolism. NF-kappa B / metabolism. RNA, Messenger / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • Hazardous Substances Data Bank. SODIUM HYDROSULFIDE .
  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. HYDROGEN SULFIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):156-7 [19038846.001]
  • (PMID = 18988885.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkynes; 0 / Apolipoproteins E; 0 / Cardiovascular Agents; 0 / Enzyme Inhibitors; 0 / I-kappa B Proteins; 0 / Lipids; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / Sulfides; 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 64165-64-6 / propargylglycine; EC 4.4.1.1 / Cystathionine gamma-Lyase; FWU2KQ177W / sodium bisulfide; TE7660XO1C / Glycine; YY9FVM7NSN / Hydrogen Sulfide
  •  go-up   go-down


50. Ruel IF, Fierrard H, Vercellino L, Bernard L, Hindie E, Duron F, Toubert ME: Pulmonary metastasis of struma ovarii: a case report. Clin Nucl Med; 2010 Sep;35(9):692-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 42-year-old woman who presented with multiple pulmonary nodules.
  • The whole-body scan showed multiple foci of pulmonary I-131 uptake, a bone metastasis of third rib, and I-131 uptake in an abdominal para-aortic lymph node.
  • At second I-131 therapy (3.8 GBq), Tg level had decreased to 14 microg/L and there was a decrease in the number of pulmonary nodular I-131 uptake, and resolution of the bone and para-aortic lymph node metastasis.
  • At third I-131 therapy (4.9 GBq), thyroglobuline was undetectable and the whole-body scan showed no I-131 uptake.
  • Struma ovarii is a rare ovarian tumor mostly benign.
  • [MeSH-minor] Adult. Female. Humans. Iodine Radioisotopes / therapeutic use. Positron-Emission Tomography. Thyroid Neoplasms / secondary. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706043.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


51. Rodondi N, Marques-Vidal P, Butler J, Sutton-Tyrrell K, Cornuz J, Satterfield S, Harris T, Bauer DC, Ferrucci L, Vittinghoff E, Newman AB, Health, Aging, and Body Composition Study: Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol; 2010 Mar 1;171(5):540-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors compared the value of 2 atherosclerosis markers (ankle-arm index (AAI) and aortic pulse wave velocity (aPWV)) and 3 inflammatory markers (C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) in predicting CHD events.
  • Among 2,191 adults aged 70-79 years at baseline (1997-1998) from the Health, Aging, and Body Composition Study cohort, the authors examined adjudicated incident myocardial infarction or CHD death ("hard" events) and "hard" events plus hospitalization for angina or coronary revascularization (total CHD events).

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] Biometrics. 1999 Jun;55(2):580-4 [11318217.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):499-511 [12551878.001]
  • [Cites] J Am Coll Cardiol. 2003 Jun 4;41(11):1886-98 [12798555.001]
  • [Cites] Circulation. 2003 Nov 11;108(19):2317-22 [14568895.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):210-5 [14722147.001]
  • [Cites] Circulation. 2004 Feb 17;109(6):733-9 [14970108.001]
  • [Cites] Circulation. 2004 Feb 24;109(7):855-60 [14757692.001]
  • [Cites] J Am Geriatr Soc. 2004 Oct;52(10):1639-47 [15450039.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] JAMA. 2004 Nov 10;292(18):2237-42 [15536110.001]
  • [Cites] Circulation. 2005 Jun 28;111(25):3384-90 [15967850.001]
  • [Cites] Circulation. 2005 Jul 5;112(1):25-31 [15983251.001]
  • [Cites] Arch Intern Med. 2005 Nov 28;165(21):2460-6 [16314541.001]
  • [Cites] Circulation. 2006 Jan 24;113(3):388-93 [16432070.001]
  • [Cites] Int J Cardiol. 2006 Jun 16;110(2):146-52 [16343662.001]
  • [Cites] Ann Intern Med. 2006 Jul 4;145(1):21-9 [16818925.001]
  • [Cites] Arch Intern Med. 2006 Jul 10;166(13):1368-73 [16832001.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Circulation. 2007 Feb 20;115(7):928-35 [17309939.001]
  • [Cites] Circulation. 2007 Jul 3;116(1):32-8 [17576871.001]
  • [Cites] JAMA. 2007 Aug 15;298(7):776-85 [17699011.001]
  • [Cites] Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12 [17569110.001]
  • [Cites] Stroke. 2008 Mar;39(3):863-9 [18258843.001]
  • [Cites] N Engl J Med. 2008 May 15;358(20):2107-16 [18480203.001]
  • [Cites] JAMA. 2008 Jul 9;300(2):197-208 [18612117.001]
  • [Cites] Ann Intern Med. 2008 Nov 18;149(10):751-60 [19017593.001]
  • [Cites] Circulation. 2009 May 5;119(17):2408-16 [19364974.001]
  • [Cites] Circulation. 2000 Jan 4-11;101(1):111-6 [10618313.001]
  • [Cites] Atherosclerosis. 2000 Feb;148(2):209-14 [10657556.001]
  • [Cites] N Engl J Med. 2000 Mar 23;342(12):836-43 [10733371.001]
  • [Cites] Circulation. 2000 Apr 18;101(15):1767-72 [10769275.001]
  • [Cites] Ann Med. 2001 Feb;33(1):37-47 [11310937.001]
  • [Cites] JAMA. 2001 Jul 11;286(2):180-7 [11448281.001]
  • (PMID = 20110287.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / N01-AG-6-2101; United States / NIA NIH HHS / AG / N01-AG-6-2103; United States / NIA NIH HHS / AG / N01-AG-6-2106; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2842214
  •  go-up   go-down


52. Kuwabara K, Ishiguro T, Ohsawa T, Sobajima J, Hatano S, Amano K, Okada N, Kumamoto K, Ishibashi K, Haga N, Ishida H: [The clinical outcome of minilaparotomy approach for curative resection of stage 0 and I colon cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2601-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their median body mass index was 22.6 kg/m2.
  • The ratio of 5-year overall survival rate was 95%, and two cases of stage I had developed a tumor recurrence (metastasis to liver and para-aortic lymph nodes), one patient died of para-aortic lymph nodes recurrence.
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224652.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Wang S, Wu D, Matthan NR, Lamon-Fava S, Lecker JL, Lichtenstein AH: Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse. Atherosclerosis; 2009 May;204(1):147-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aortic and elicited peritoneal macrophage (Mphi) total cholesterol were 24% (P=0.07) and 25% (P<0.05) lower, respectively, in HSF R=1:1 compared to HSF omega-6 fed mice.
  • These data suggest that lower omega-6:EPA+DHA ratio diets lowered some measures of inflammation and Mphi cholesterol accumulation, which was associated with less aortic lesion formation in LDLr-/- mice.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2007 Jul;137(7):1776-82 [17585030.001]
  • [Cites] Thromb Res. 2005;116(5):393-401 [16122552.001]
  • [Cites] FEBS Lett. 2007 Sep 18;581(23):4389-96 [17719033.001]
  • [Cites] J Cyst Fibros. 2008 Jan;7(1):68-78 [17889625.001]
  • [Cites] Eur J Nutr. 2008 Apr;47(3):153-60 [18454337.001]
  • [Cites] J Lipid Res. 2005 Oct;46(10):2061-71 [16024915.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):35896-903 [16118212.001]
  • [Cites] Atherosclerosis. 2005 Dec;183(2):301-7 [16285993.001]
  • [Cites] Am J Cardiol. 2005 Dec 1;96(11):1521-9 [16310434.001]
  • [Cites] Atherosclerosis. 2006 Jan;184(1):78-85 [15946668.001]
  • [Cites] Br J Nutr. 2006 May;95(5):849-59 [16611374.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 May;26(5):995-1001 [16484595.001]
  • [Cites] Am J Clin Nutr. 2006 Jul;84(1):5-17 [16825676.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1702-11 [16728653.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1864-70 [16741149.001]
  • [Cites] Am J Cardiol. 2006 Aug 21;98(4A):19i-26i [16919513.001]
  • [Cites] Am J Clin Nutr. 2006 Sep;84(3):497-504 [16960162.001]
  • [Cites] Am J Clin Nutr. 2006 Sep;84(3):513-22 [16960164.001]
  • [Cites] Cytokine. 2006 Sep;35(5-6):258-62 [17070067.001]
  • [Cites] Atherosclerosis. 2007 Mar;191(1):11-21 [16730733.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5207-16 [17186944.001]
  • [Cites] Nutr Rev. 2000 Feb;58(2 Pt 1):56-9 [10748610.001]
  • [Cites] Nat Med. 2001 Jan;7(1):53-8 [11135616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):507-12 [11149950.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38378-87 [11504730.001]
  • [Cites] Am J Cardiol. 2001 Nov 15;88(10):1139-42 [11703959.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Infect Immun. 2002 Jun;70(6):2995-3003 [12010990.001]
  • [Cites] Atherosclerosis. 2002 Nov;165(1):89-100 [12208474.001]
  • [Cites] Diabetes. 2002 Oct;51(10):2922-8 [12351428.001]
  • [Cites] Circulation. 2002 Nov 19;106(21):2747-57 [12438303.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49982-8 [12376530.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):10983-92 [12529332.001]
  • [Cites] J Lipid Res. 2003 Apr;44(4):800-6 [12562840.001]
  • [Cites] Atherosclerosis. 2003 Oct;170(2):277-83 [14612208.001]
  • [Cites] Ann Med. 2004;36(2):98-118 [15119830.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):969-73 [15159225.001]
  • [Cites] Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10 [15173056.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8797-802 [15169957.001]
  • [Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III20-6 [15198962.001]
  • [Cites] J Nutr. 2004 Jul;134(7):1806-11 [15226473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11529-30 [15292506.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1621-7 [15231516.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):1029-35 [15447916.001]
  • [Cites] Am J Cardiol. 2004 Oct 1;94(7):901-6 [15464673.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2445-51 [9278337.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 1):C661-8 [9730949.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):275-81 [9734366.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Nov;18(11):1818-27 [9812923.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):29-33 [10092505.001]
  • [Cites] Atherosclerosis. 1999 Jul;145(1):51-60 [10428295.001]
  • [Cites] J Clin Invest. 1999 Oct;104(8):R25-31 [10525055.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):e174-8 [15331433.001]
  • [Cites] Clin Chem Lab Med. 2004;42(10):1132-9 [15552272.001]
  • [Cites] Circulation. 2004 Dec 7;110(23):3604-9 [15569842.001]
  • [Cites] Eur J Clin Invest. 2005 Jan;35(1):52-9 [15638820.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):867-74 [15698426.001]
  • [Cites] J Nutr. 2005 Mar;135(3):492-8 [15735083.001]
  • [Cites] Atheroscler Suppl. 2005 May;6(2):21-9 [15823493.001]
  • [Cites] J Nutr Biochem. 2005 Jun;16(6):368-74 [15936649.001]
  • [Cites] Biochim Biophys Acta. 2005 Jun 15;1735(1):1-19 [15922656.001]
  • [Cites] Eur J Nutr. 2007 Sep;46(6):321-8 [17712587.001]
  • (PMID = 18842266.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL054727-07; United States / NHLBI NIH HHS / HL / R01 HL 54727; United States / NHLBI NIH HHS / HL / HL054727-04; United States / NHLBI NIH HHS / HL / R01 HL054727-06; United States / NHLBI NIH HHS / HL / R01 HL054727-04; United States / NHLBI NIH HHS / HL / R01 HL054727-05; United States / NHLBI NIH HHS / HL / T32 HL69772-01A1; United States / NHLBI NIH HHS / HL / T32 HL069772; United States / NHLBI NIH HHS / HL / T32 HL069772-01A1; United States / NHLBI NIH HHS / HL / HL054727-07; United States / NHLBI NIH HHS / HL / R01 HL054727-03; United States / NHLBI NIH HHS / HL / HL054727-06; United States / NHLBI NIH HHS / HL / HL054727-05; United States / NHLBI NIH HHS / HL / HL054727-03; United States / NHLBI NIH HHS / HL / R01 HL054727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / ATP Binding Cassette Transporter 1; 0 / Antigens, CD36; 0 / Ccl2 protein, mouse; 0 / Chemokine CCL2; 0 / Dietary Fats; 0 / Fatty Acids, Omega-6; 0 / Inflammation Mediators; 0 / Interleukin-6; 0 / Lipoproteins; 0 / RNA, Messenger; 0 / Receptors, LDL; 0 / Scarb1 protein, mouse; 0 / Scavenger Receptors, Class B; 0 / Tumor Necrosis Factor-alpha; 25167-62-8 / Docosahexaenoic Acids; 97C5T2UQ7J / Cholesterol; AAN7QOV9EA / Eicosapentaenoic Acid
  • [Other-IDs] NLM/ NIHMS177443; NLM/ PMC2826705
  •  go-up   go-down


54. Cypiene A, Laucevicius A, Venalis A, Ryliskyte L, Dadoniene J, Petrulioniene Z, Kovaite M, Laskova V, Gintautas J: Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). Proc West Pharmacol Soc; 2007;50:119-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this clinical work was to determine the modification of carotid-radial pulse wave velocity (PWV) and aortic augmentation index (AIx) in young-aged RA patients and the influence of treatment with anti-TNF-alpha (infliximab) on these measures.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Arteries / physiology. Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / pathology. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Body Mass Index. Carotid Arteries / pathology. Elasticity. Female. Humans. Infliximab. Male. Manometry. Risk Factors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18605247.001).
  • [ISSN] 0083-8969
  • [Journal-full-title] Proceedings of the Western Pharmacology Society
  • [ISO-abbreviation] Proc. West. Pharmacol. Soc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


55. Zhao H, Ito A, Kimura SH, Yabuta N, Sakai N, Ikawa M, Okabe M, Matsuzawa Y, Yamashita S, Nojima H: RECS1 deficiency in mice induces susceptibility to cystic medial degeneration. Genes Genet Syst; 2006 Feb;81(1):41-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To understand the function of RECS1 in the body, we made RECS1 knockout (KO) mice and found that RECS1 KO mice (older than 14 months) are prone to cystic medial degeneration (CMD).
  • [MeSH-major] Aortic Aneurysm / genetics. Aortic Aneurysm / pathology. Genetic Predisposition to Disease. Membrane Proteins / deficiency. Membrane Proteins / genetics. Muscle, Smooth, Vascular / metabolism. Muscle, Smooth, Vascular / pathology
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line. Cell Line, Tumor. Endosomes / metabolism. HeLa Cells. Humans. Intracellular Membranes / metabolism. Lysosomes / metabolism. Mice. Mice, Knockout. Molecular Sequence Data. Stress, Mechanical


56. Ueno H, Koyama H, Shoji T, Monden M, Fukumoto S, Tanaka S, Otsuka Y, Mima Y, Morioka T, Mori K, Shioi A, Yamamoto H, Inaba M, Nishizawa Y: Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis; 2010 Aug;211(2):431-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aortic atherosclerosis was morphometrically determined.
  • RESULTS: ApoE(-/-)RAGE(-/-) mice exhibited significantly less total aortic plaque area than apoE(-/-)RAGE(+/+) mice.
  • Body weight, epididymal fat weight, and epididymal adipocyte size were also significantly less in apoE(-/-)RAGE(-/-) mice than apoE(-/-)RAGE(+/+) mice.
  • Serum adiponectin, but not tumor necrosis factor-alpha, was significantly higher in apoE(-/-)RAGE(-/-) mice than apoE(-/-)RAGE(+/+) mice.
  • Simple regression analysis revealed that the total aortic plaque area was positively associated with epididymal fat weight, epididymal adipocyte size, and negatively with serum adiponectin levels.
  • Multiple regression analyses revealed that RAGE genotype and serum adiponectin were mutually interrelated in determining aortic atherosclerosis.
  • [MeSH-minor] Animal Feed. Animals. Atherosclerosis. Diet, Atherogenic. Immunohistochemistry / methods. Male. Mice. Mice, Inbred C57BL. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20435311.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Apolipoproteins E; 0 / Glycosylation End Products, Advanced; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


57. Hamsa TP, Kuttan G: Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol; 2010 Dec 15;649(1-3):64-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
  • Intraperitoneal administration of harmine at 10 mg/kg body weight significantly decreased tumour directed capillary formation.
  • At the same time harmine increased anti-tumour factors like interleukin-2 (IL-2) and tissue inhibitor metalloprotease (TIMP).
  • Moreover nuclear factor (NF)-κB and other transcription factors like CREB, ATF-2 involved in tumour development and angiogenesis were also inhibited by harmine.
  • Direct treatment of the harmine also inhibited microvessel outgrowth from the rat aortic ring.
  • Production of other factors by tumour cells which are involved in angiogenesis like cyclooxygenase (COX-2), inducible nitric oxide synthase (iNOS) and matrix metalloproteases (MMPs) were also decrease by the treatment with harmine.
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. In Vitro Techniques. Male. Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Melanoma, Experimental / metabolism. Mice. Mice, Inbred C57BL. Microvessels / drug effects. RNA, Messenger / metabolism. Rats. Vascular Endothelial Growth Factors / blood. Vascular Endothelial Growth Factors / genetics. Vascular Endothelial Growth Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20858484.001).
  • [ISSN] 1879-0712
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiogenic Proteins; 0 / Antineoplastic Agents, Phytogenic; 0 / Inflammation Mediators; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factors; 4FHH5G48T7 / Harmine
  •  go-up   go-down


58. Mac Grory B, O'Connor ET, O'Halloran KD, Jones JF: The effect of pro-inflammatory cytokines on the discharge rate of vagal nerve paraganglia in the rat. Respir Physiol Neurobiol; 2010 Apr 30;171(2):122-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vagal paraganglia resemble the carotid body and are chemosensitive to reduction in the partial pressure of oxygen (P O2) (O'Leary et al., 2004).
  • We hypothesised that they may also mediate communication between the immune system and the central nervous system and more specifically respond to the pro-inflammatory cytokines: interleukin-1 beta (IL-1 beta) and tumour necrosis factor-alpha (TNF-alpha).
  • We recorded axonal firing rate of isolated superfused rat glomus cells - located at the bifurcation of the superior laryngeal nerve - to IL-1 beta or TNF-alpha at concentrations of 0.5 ng/ml, 5 ng/ml and 50 ng/ml.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • [Cites] Nature. 2002 Dec 19-26;420(6917):853-9 [12490958.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Feb;296(2):L158-66 [18978039.001]
  • [Cites] Circ Res. 1970 Feb;26(2):235-47 [5412537.001]
  • [Cites] J Physiol. 1981 Nov;320:309-18 [7320939.001]
  • [Cites] J Neurocytol. 1987 Jun;16(3):289-97 [3612181.001]
  • [Cites] J Physiol. 1997 Jul 15;502 ( Pt 2):461-7 [9263924.001]
  • [Cites] J Physiol. 1999 Feb 1;514 ( Pt 3):821-8 [9882753.001]
  • [Cites] J Neurosci. 1999 Apr 1;19(7):2799-806 [10087091.001]
  • [Cites] Obes Rev. 2007 Mar;8(2):119-27 [17300278.001]
  • [Cites] Respir Physiol Neurobiol. 2007 May 14;156(2):116-9 [17182290.001]
  • [Cites] Mitochondrion. 2007 Jul;7(4):284-7 [17395552.001]
  • [Cites] Eur J Neurosci. 2007 Jun;25(12):3638-47 [17610583.001]
  • [Cites] Exp Physiol. 2008 Jul;93(7):892-907 [18562477.001]
  • [Cites] Histochem Cell Biol. 2008 Sep;130(3):549-59 [18446360.001]
  • [Cites] Respir Physiol Neurobiol. 2004 Jul 20;141(2):137-44 [15239964.001]
  • (PMID = 20211277.001).
  • [ISSN] 1878-1519
  • [Journal-full-title] Respiratory physiology & neurobiology
  • [ISO-abbreviation] Respir Physiol Neurobiol
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Transcription Factor RelA; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC2958315
  •  go-up   go-down


59. Uren RF, Howman-Giles RB, Chung D, Thompson JF: Role of lymphoscintigraphy for selective sentinel lymphadenectomy. Cancer Treat Res; 2005;127:15-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An essential prerequisite for a successful sentinel node biopsy (SNB) procedure is an accurate map of the pattern of lymphatic drainage from the primary tumor site.
  • The SN is not always found in the nearest node field and is best defined as "any lymph node receiving direct lymphatic drainage from a primary tumor site."
  • Unexpected lymphatic drainage has been found from the skin of the back to SNs in the triangular intermuscular space and in some patients through the posterior body wall to SNs in the para-aortic, paravertebral, and retroperitoneal areas.
  • Interval nodes, which lie along the course of a lymphatic vessel between a melanoma site and a recognised node field, are not uncommon especially on the trunk.
  • Drainage across the midline of the body is quite frequent on the trunk and in the head and neck region.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209076.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


60. Fuentes S, Malikov S, Blondel B, Métellus P, Dufour H, Grisoli F: Cervicosternotomy as an anterior approach to the upper thoracic and cervicothoracic spinal junction. J Neurosurg Spine; 2010 Feb;12(2):160-4
MedlinePlus Health Information. consumer health - Spinal Cord Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When operating on this specific area (for tumor or trauma), the aim is generally to decompress and stabilize the spine.
  • The vertebral lesion was due to trauma in 4 cases and tumor in the other 3.
  • A single vertebral body was involved in 2 cases, 2 in 3 cases, and 3 in 2 cases.
  • All patients underwent the same preoperative workup: CT scanning, MR imaging, and CT angiography of the aortic arch.

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20121350.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Soteras Roura C, Bustos García de Castro A, Cabeza Martínez B, Ferreirós Domínguez J: [Mediastinal paragangliomas: a report of 2 cases]. Radiologia; 2009 Jul-Aug;51(4):420-3
Genetic Alliance. consumer health - Paragangliomas 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We illustrate and describe the imaging findings in two cases of mediastinal paraganglioma, one nonfunctional aorticopulmonary paraganglioma and one locally aggressive functional aorticosympathetic paraganglioma first observed as a mediastinal mass on chest plain-film radiographs.
  • [MeSH-major] Mediastinal Neoplasms. Paraganglioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298985.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Yanbuloğlu B, Celebi I, Yanbuloğlu U, Vural C: Two synchronous glomus tumors simulating a single mass: glomus vagale and glomus caroticum. Diagn Interv Radiol; 2006 Dec;12(4):177-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two synchronous glomus tumors simulating a single mass: glomus vagale and glomus caroticum.
  • Glomus tumors, especially with some definitive MR imaging features, are diagnosed easily.
  • However, when two glomus tumors are suspected in one single mass, careful evaluation is necessary.
  • We report one patient with two synchronous glomus tumors, ipsilateral glomus tumor of the carotid body and glomus vagale on the right neck, simulating a single mass.
  • [MeSH-major] Aortic Bodies. Carotid Body. Glomus Tumor / diagnosis. Head and Neck Neoplasms / diagnosis
  • [MeSH-minor] Angiography. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Glomus Vagale Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160800.001).
  • [ISSN] 1305-3825
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


63. Hataji K, Ami K, Nagahama T, Ohara T, Ganno H, Kawasaki N, Fukuda A, Ando M, Arai K, Tei S: [A case of unresectable cardiac gastric cancer patient who maintained a long-term QOL with chemotherapy and detention of metallic stent]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2290-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He visited our hospital for dysphagia, abdominal distention and body weight loss.
  • He was underwent gastro-endoscopy and made a diagnosis of the advanced cardiac gastric cancer.
  • Furthermore, computed tomography was performed and detected multiple liver and spleen, para-aortic lymph-node metastases and the ascites (suspected for dissemination).
  • The main tumor and multiple metastatic lesions were reduced.
  • But after six months, a tumor marker was increased.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037399.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Sai M, Mori H, Kiyonaga M, Kosen K, Yamada Y, Matsumoto S: Peripancreatic lymphatic invasion by pancreatic carcinoma: evaluation with multi-detector row CT. Abdom Imaging; 2010 Apr;35(2):154-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from the region around the pancreatic body and tail, normal peripancreatic lymphatic networks were detected as "linear structures" on MDCT.
  • Peripancreatic lymphatic invasion by pancreatic carcinoma was more frequently detected around the common hepatic artery, celiac artery, superior mesenteric artery, and left para-aortic area.
  • Depending on the tumor location, positive peripancreatic lymphatic invasion was most frequent at the area around the common hepatic artery in the head region and at the area around the celiac artery in the body and tail regions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / radiography. Radiographic Image Interpretation, Computer-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972151.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


65. Stompor T, Rajzer M, Sułowicz W, Dembińska-Kieć A, Janda K, Kawecka-Jaszcz K, Wójcik K, Tabor B, Zdzienicka A, Janusz-Grzybowska E: [Markers of inflammation and large artery compliance in patients with chronic renal failure]. Pol Merkur Lekarski; 2006 Aug;21(122):111-4; discussion 115-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was to evaluate the possible relationship between aortic pulse wave velocity (AoPWV), considered useful tool of aortic stiffness assessment and blood pressure parameters, anthropometric characteristics, pro-inflammatory cytokines and acute phase reactants in patients treated with PD.
  • In all patients Tumor Necrosis Factor alpha (TNF alpha), interleukin 6 (IL-6), C- reactive protein and fibrinogen were assayed as 'markers of inflammation'.
  • Significant correlations were found between AoPWV, age, body weight and BMI.
  • CONCLUSION: Chronic, uremia-dependent inflammation may be one of the factors influencing aortic stiffness in patients treated with PD.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144091.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Biomarkers; 0 / Cytokines; 0 / Growth Substances
  •  go-up   go-down


66. Stein JP: Lymphadenectomy in bladder cancer: how high is "high enough"? Urol Oncol; 2006 Jul-Aug;24(4):349-55
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The role of a regional lymphadenectomy in the surgical treatment of high-grade, invasive transitional cell carcinoma of the bladder has evolved over the last several decades.
  • Although the application of a lymphadenectomy for bladder cancer is not significantly debated, the absolute extent or level of proximal dissection of the lymphadenectomy remains a controversial issue.
  • RESULTS: A growing body of evidence, spanning from early autopsy and cadaveric studies to recent retrospective series and multicenter prospective trials, suggests that an extended lymph node dissection (cephalad extent to include the common iliac arteries) may provide not only prognostic information but also provide a therapeutic benefit for both patients with lymph node-positive and lymph node-negative disease undergoing radical cystectomy for bladder cancer.
  • The need to extend the dissection higher to include the distal para-aortic and paracaval lymph nodes may be important in select individuals but remains more controversial.
  • The extent of the primary bladder tumor (p-stage), number of lymph nodes removed, the lymph node tumor burden (tumor volume), and lymph node density (number of lymph nodes involved/number of lymph nodes removed) are all important prognostic variables in patients undergoing cystectomy with pathologic evidence of lymph node metastases.

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818190.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Stein JP, Skinner DG: The role of lymphadenectomy in high-grade invasive bladder cancer. Urol Clin North Am; 2005 May;32(2):187-97
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the extent or absolute limits of the lymph node dissection are unknown and remain to be better defined, an ever-growing body of data supports a more extended lymphadenectomy at the time of cystectomy in all patients who are appropriate surgical candidates.
  • An extended lymph node dissection should include the distal para-aortic and paracaval lymph nodes as well as the pre-sacral nodes, known anatomic sites of lymph node drainage from the bladder and potential sites of lymph node metastases in patients with bladder cancer.
  • The extent of the primary bladder tumor (p stage), the number of lymph nodes removed, and the lymph node tumor burden are important prognostic variables in patients undergoing cystectomy with pathologic evidence of lymph node metastases.
  • This concept simultaneously incorporates the lymph node tumor burden (number of lymph nodes involved) and the number of lymph nodes removed (extent of the lymphadenectomy), improving the stratification of lymph node-positive patients following radical cystectomy.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15862616.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


68. Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B: Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation; 2008 Jan 22;117(3):421-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have shown previously that the dithiol compound alpha-lipoic acid (LA) exerts antiinflammatory effects by inhibiting tumor necrosis factor-alpha- and lipopolysaccharide-induced endothelial and monocyte activation in vitro and lipopolysaccharide-induced acute inflammatory responses in vivo.
  • Supplementation with LA significantly reduced atherosclerotic lesion formation in the aortic sinus of both mouse models by approximately 20% and in the aortic arch and thoracic aorta of apoE-/- and apoE/low-density lipoprotein receptor-deficient mice by approximately 55% and 40%, respectively.
  • This strong antiatherogenic effect of LA was associated with almost 40% less body weight gain and lower serum and very low-density lipoprotein levels of triglycerides but not cholesterol.
  • In addition, LA supplementation reduced aortic expression of adhesion molecules and proinflammatory cytokines and aortic macrophage accumulation.
  • These antiinflammatory effects of LA were more pronounced in the aortic arch and the thoracic aorta than in the aortic sinus, reflecting the corresponding reductions in atherosclerosis.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158360.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL079382; United States / NCCIH NIH HHS / AT / AT002034; United States / NHLBI NIH HHS / HL / HL60886; United States / NIEHS NIH HHS / ES / ES11542; United States / NHLBI NIH HHS / HL / HL079382
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Receptors, LDL; 0 / Triglycerides; 73Y7P0K73Y / Thioctic Acid; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


69. Chen X, Zhang H, McAfee S, Zhang C: The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol; 2010 Sep;299(3):H605-12
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesized that the reciprocal association between adiponectin and lectin-like oxidized LDL (ox-LDL) receptor (LOX)-1 contributes to the regulation of aortic endothelial dysfunction in atherosclerosis.
  • To test this hypothesis, endothelium-dependent (ACh) and endothelium-independent (sodium nitroprusside) vasorelaxation of isolated aortic rings from control mice, apolipoprotein E (ApoE) knockout (KO) mice, and ApoE KO mice treated with either adiponectin (15 microg x day(-1) x mouse(-1) sc for 8 days) or neutralizing antibody to LOX-1 (anti-LOX-1, 16 microg/ml, 0.1 ml/mouse ip for 7 days) were examined.
  • Aortic ROS formation and ox-LDL uptake were increased in ApoE KO mice.
  • Both adiponectin and anti-LOX-1 treatment reduced ROS production and aortic ox-LDL uptake.
  • Although adiponectin expression was lower in ApoE KO versus control mice, anti-LOX-1 increased aortic adiponectin expression, suggesting a reciprocal regulation between adiponectin and LOX-1.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 1999 Dec 21-28;100(25):2473-6 [10604883.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1208-16 [19666844.001]
  • [Cites] Br J Pharmacol. 2000 Nov;131(5):921-6 [11053212.001]
  • [Cites] Circulation. 2001 Feb 27;103(8):1057-63 [11222466.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):541-6 [11511093.001]
  • [Cites] Circulation. 2002 Jun 18;105(24):2893-8 [12070119.001]
  • [Cites] Circulation. 2002 Nov 26;106(22):2767-70 [12451000.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2461-8 [12431986.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):924-9 [15033490.001]
  • [Cites] Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32 [15198963.001]
  • [Cites] Physiol Rev. 2004 Oct;84(4):1381-478 [15383655.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1996 Jul;16(7):831-42 [8673557.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2137-42 [15345516.001]
  • [Cites] Hypertension. 2004 Dec;44(6):956-62 [15505117.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):29-38 [15539615.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 May;288(5):R1220-5 [15604306.001]
  • [Cites] Diabetes. 2005 May;54(5):1506-13 [15855339.001]
  • [Cites] Clin Med Res. 2006 Mar;4(1):53-65 [16595793.001]
  • [Cites] J Am Coll Cardiol. 2006 Sep 5;48(5):980-2 [16949490.001]
  • [Cites] Eur J Pharmacol. 2006 Oct 10;547(1-3):22-30 [16963021.001]
  • [Cites] Curr Med Chem. 2007;14(2):243-8 [17266583.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):871-7 [17272755.001]
  • [Cites] Diabetes. 2007 May;56(5):1387-94 [17287464.001]
  • [Cites] Atherosclerosis. 2007 Jul;193(1):20-7 [17055514.001]
  • [Cites] Circ Res. 2007 Jun 8;100(11):1634-42 [17478727.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R47-54 [17363678.001]
  • [Cites] J Immunol. 2007 Sep 1;179(5):3242-8 [17709540.001]
  • [Cites] Cancer Lett. 2007 Dec 8;258(1):31-7 [17868983.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1836-44 [17940218.001]
  • [Cites] FEBS Lett. 2008 May 28;582(12):1719-24 [18455514.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Oct 24;375(3):390-4 [18703020.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2009 Jan;6(1):27-35 [19029992.001]
  • [Cites] Atherosclerosis. 2009 Jan;202(1):152-61 [18511057.001]
  • [Cites] J Mol Cell Cardiol. 2009 Mar;46(3):413-9 [19027750.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1164-71 [19478208.001]
  • [Cites] J Pharmacol Sci. 2009 Jul;110(3):362-9 [19609067.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1328-35 [19667111.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1296-301 [10982546.001]
  • (PMID = 20581092.001).
  • [ISSN] 1522-1539
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL077566-03; United States / NHLBI NIH HHS / HL / HL085119-03; United States / NHLBI NIH HHS / HL / R01 HL077566; United States / NHLBI NIH HHS / HL / HL085119-05; United States / NHLBI NIH HHS / HL / R01-HL-077566; United States / NHLBI NIH HHS / HL / R01 HL085119; United States / NHLBI NIH HHS / HL / HL077566-04; United States / NHLBI NIH HHS / HL / R01 HL085119-04; United States / NHLBI NIH HHS / HL / R01 HL085119-05; United States / NHLBI NIH HHS / HL / R01 HL077566-04; United States / NHLBI NIH HHS / HL / HL077566-03; United States / NHLBI NIH HHS / HL / HL085119-04; United States / NHLBI NIH HHS / HL / R01 HL085119-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Apolipoproteins E; 0 / Nitric Oxide Donors; 0 / Olr1 protein, mouse; 0 / Reactive Oxygen Species; 0 / Scavenger Receptors, Class E; 0 / Tumor Necrosis Factor-alpha; 169D1260KM / Nitroprusside; 31C4KY9ESH / Nitric Oxide; N9YNS0M02X / Acetylcholine
  • [Other-IDs] NLM/ PMC2944476
  •  go-up   go-down


70. Oshima N, Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Sugisawa N, Taki Y, Motegi Y, Boku N, Sasaki K, Terashima M: [Histological complete response in a case of advanced gastric cancer treated by neo-adjuvant chemotherapy with S-1/CDDP]. Gan To Kagaku Ryoho; 2010 Apr;37(4):697-701
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 59-year-old male was found to have advanced gastric cancer with multiple lymph node metastasis including para-aortic lymph nodes(cT3, cN3, cM0, cH0, cP0, cStage IV).
  • Since curative surgery was deemed not feasible, we tried neoadjuvant chemotherapy expecting downstaging of the tumor.
  • S-1(120 mg/body)was orally administered for three weeks followed by one week rest, and CDDP(60 mg/m2)was administered on day 8.
  • Laparotomy revealed neither ascites nor peritoneal dissemination, and he underwent total gastrectomy, splenectomy and D2+para-aortic lymph node dissection with curative intent.
  • The histological diagnosis revealed complete disappearance of cancer cells in the primary lesion of the stomach and lymph nodes, confirming a pathological complete response.
  • [MeSH-minor] Drug Combinations. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414029.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


71. Chapman DB, Lippert D, Geer CP, Edwards HD, Russell GB, Rees CJ, Browne JD: Clinical, histopathologic, and radiographic indicators of malignancy in head and neck paragangliomas. Otolaryngol Head Neck Surg; 2010 Oct;143(4):531-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The odds ratio for a patient with pain having a malignant tumor was 36 (95% CI: 5.5-234).
  • In a secondary analysis of carotid body tumors alone, enlarging neck mass was not found to be significant between benign and malignant disease (P = 0.14).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Paraganglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aortic Bodies / pathology. Carotid Body Tumor / diagnosis. Carotid Body Tumor / pathology. Carotid Body Tumor / radiography. Female. Glomus Jugulare Tumor / diagnosis. Glomus Jugulare Tumor / pathology. Glomus Jugulare Tumor / radiography. Glomus Tympanicum Tumor / diagnosis. Glomus Tympanicum Tumor / pathology. Glomus Tympanicum Tumor / radiography. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Academy of Otolaryngology–Head and Neck Surgery Foundation. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20869564.001).
  • [ISSN] 1097-6817
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Hinerman RW, Amdur RJ, Morris CG, Kirwan J, Mendenhall WM: Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience. Head Neck; 2008 Nov;30(11):1431-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An evaluation of the treatment results for 104 patients with 121 paragangliomas of the temporal bone, carotid body, and/or glomus vagale who were treated with radiation therapy (RT) at the University of Florida between 1968 and 2004.
  • CONCLUSION: Fractionated RT offers a high probability of tumor control with minimal risks for patients with paragangliomas of the temporal bone and neck.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Paraganglioma, Extra-Adrenal / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aortic Bodies / radiation effects. Carotid Body / radiation effects. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiosurgery / methods. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant / methods. Radiotherapy, Conformal / methods. Radiotherapy, Intensity-Modulated / methods. Retrospective Studies. Survival Analysis. Temporal Bone / radiation effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. Head Neck, 2008.
  • (PMID = 18704974.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M: [Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1761-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Starting in October 2004, 100 mg/day of TS-1 was administered for 3 weeks; intravenous drip infusion of 100 mg/body of CDDP was conducted in the second week for a period of 24 hours.
  • After 3 courses of this regimen, a fiber optic examination of the colon conducted in February 2005 no longer detected the rectal tumor, leaving only a cicatrix.
  • Upon a CT examination, the para-aortic lymph nodes that had been enlarged were notably reduced in size and an improvement was eminent in the hypertrophic rectal wall.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315933.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


74. Shen J, Chandrasekharan UM, Ashraf MZ, Long E, Morton RE, Liu Y, Smith JD, DiCorleto PE: Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis. Circ Res; 2010 Mar 19;106(5):902-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 3 groups of mice exhibited similar body weight and serum lipid profiles; however, both MKP-1(+/-) and MKP-1(-/-) mice had significantly less aortic root atherosclerotic lesion formation than MKP-1(+/+) mice.
  • The reduction in atherosclerosis was accompanied by decreased plasma levels of interleukin-1alpha and tumor necrosis factor alpha, and preceded by increased antiinflammatory cytokine interleukin-10.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 May;20(5):1179-81 [10807729.001]
  • [Cites] J Biol Chem. 2009 Nov 6;284(45):30815-24 [19748894.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17030-5 [11278958.001]
  • [Cites] Sheng Li Xue Bao. 2000 Oct;52(5):365-70 [11941388.001]
  • [Cites] Circulation. 2002 Jul 2;106(1):36-42 [12093767.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):868-74 [12490960.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 28;303(1):74-80 [12646169.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):12-22 [14604830.001]
  • [Cites] Cell Signal. 2004 Jul;16(7):769-79 [15115656.001]
  • [Cites] Cell. 2004 Jun 11;117(6):699-711 [15186772.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1676-81 [15242861.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Oct;31(4):423-31 [15231489.001]
  • [Cites] Atherosclerosis. 2004 Oct;176(2):233-45 [15380445.001]
  • [Cites] Nature. 1992 Oct 15;359(6396):644-7 [1406996.001]
  • [Cites] Cell. 1993 Nov 5;75(3):487-93 [8221888.001]
  • [Cites] J Biol Chem. 1996 Jan 5;271(1):544-7 [8550616.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46678-85 [15339908.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1899-907 [16424221.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):15-20 [16380512.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):131-40 [16380513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2274-9 [16461893.001]
  • [Cites] Cell Metab. 2006 Jul;4(1):61-73 [16814733.001]
  • [Cites] Methods Mol Med. 2006;129:83-95 [17085806.001]
  • [Cites] J Cell Sci. 2006 Nov 15;119(Pt 22):4607-15 [17093265.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):e16-7 [17301316.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Mar;8(3):234-44 [17318227.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jan;294(1):C241-50 [18003751.001]
  • [Cites] Circ Res. 2008 Feb 29;102(4):448-56 [18174464.001]
  • [Cites] Circ Res. 2008 Sep 26;103(7):726-32 [18723442.001]
  • [Cites] Am J Physiol Cell Physiol. 2009 Feb;296(2):C242-9 [19020052.001]
  • [Cites] J Lipid Res. 2000 Jun;41(6):1020-6 [10828095.001]
  • (PMID = 20093631.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL029582-26A18736; United States / NHLBI NIH HHS / HL / P01 HL029582; United States / NHLBI NIH HHS / HL / HL29582; United States / NHLBI NIH HHS / HL / P01 HL029582-26A18736
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Chemokine CXCL12; 0 / Cxcl12 protein, mouse; 0 / Inflammation Mediators; 0 / Interleukin-1alpha; 0 / Lipids; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.3.48 / Dual Specificity Phosphatase 1; EC 3.1.3.48 / Dusp1 protein, mouse
  • [Other-IDs] NLM/ NIHMS181151; NLM/ PMC2847792
  •  go-up   go-down


75. Paris J, Facon F, Thomassin JM, Zanaret M: Cervical paragangliomas: neurovascular surgical risk and therapeutic management. Eur Arch Otorhinolaryngol; 2006 Sep;263(9):860-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 29 carotid body tumors and 11 vagal body tumors.
  • Only one patient had a malignant paraganglioma.
  • A vascular repair procedure was performed in 10% and always occurred in carotid body tumors including the malignant one.
  • Paralysis of vagus nerve was reported in 11 cases (27.5%), nine of whom were patients with vagal body tumors.
  • Early management of patients prevents progressive neurological deficit due to an enlarging tumor mass and minimizes neurovascular complications.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Neck / surgery. Paraganglioma / surgery. Postoperative Complications
  • [MeSH-minor] Adult. Aortic Bodies / surgery. Carotid Body / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nervous System Diseases / etiology. Perioperative Care. Retrospective Studies. Risk Factors. Sex Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16823560.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Zhao QM, Yan D, Song AL, Wang W, Shi Q, Wang LY, Chen D, Fang W, Wu Y, Xu JP, Chen X, Chen TJ, Mi SH, Lü SZ: [Rosiglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice]. Zhonghua Xin Xue Guan Bing Za Zhi; 2005 May;33(5):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to normal diet, rosiglitazone group received rosiglitazone 17 mg/kg of body weight/day.
  • Venous bloods were collected for plasma glucose and lipid analysis, and aorta were prepared for morphologic and immunohistochemical analysis after 14 weeks.
  • Aortic root (1 cm) was cut and prepared for paraffin slice.
  • The histomorphometric analysis of atherosclerotic lesion was performed by means of HE; positive percentage of macrophage cell and tumor necrosis factor-alpha were measured by means of immunohistochemistry in cross section.
  • The ratio of lesion/aortic wall surface in the rest aorta was measured by means of Sudan IV staining in longitudinal section.
  • Rosiglitazone could significantly reduce the extend of atherosclerosis of longitudinal section, decrease the amount of macrophage cell and the level of tumor necrosis factor-alpha in lesions.
  • CONCLUSION: Rosiglitazone suppresses the expression of tumor necrosis factor-alpha, reduces the number of macrophage cell in lesion, and inhibits the development of atherosclerosis.
  • [MeSH-minor] Animals. Aorta / pathology. Blood Glucose / analysis. Body Weight / drug effects. Cholesterol, HDL / blood. Cholesterol, LDL / blood. Female. Macrophages / pathology. Male. Mice. Mice, Knockout. Tumor Necrosis Factor-alpha / biosynthesis

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15932692.001).
  • [ISSN] 0253-3758
  • [Journal-full-title] Zhonghua xin xue guan bing za zhi
  • [ISO-abbreviation] Zhonghua Xin Xue Guan Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Blood Glucose; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Hypoglycemic Agents; 0 / Thiazolidinediones; 0 / Tumor Necrosis Factor-alpha; 05V02F2KDG / rosiglitazone
  •  go-up   go-down


77. Nedergaard J, Bengtsson T, Cannon B: Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab; 2007 Aug;293(2):E444-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, serendipidously, as a consequence of the use of fluorodeoxyglucose positron emission tomography (FDG PET) to trace tumor metastasis, observations that may change that notion have recently been made.
  • These tomography scans have visualized symmetrical areas of increased tracer uptake in the upper parts of the human body; these areas of uptake correspond to brown adipose tissue.
  • The human depots are somewhat differently located from those in rodents, the main depots being found in the supraclavicular and the neck regions with some additional paravertebral, mediastinal, para-aortic, and suprarenal localizations (but no interscapular).
  • [MeSH-minor] Adult. Age Factors. Body Weight / physiology. Cold Temperature. Fluorodeoxyglucose F18 / pharmacokinetics. Glucose / metabolism. Humans. Incidental Findings. Models, Biological. Positron-Emission Tomography. Sex Characteristics. Sympathetic Nervous System / physiology. Thermogenesis / physiology

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E1129 [17911351.001]
  • (PMID = 17473055.001).
  • [ISSN] 0193-1849
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  • [Number-of-references] 70
  •  go-up   go-down


78. Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM: Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology (Oxford); 2005 Dec;44(12):1503-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Takayasu arteritis (TA) is a chronic inflammatory disorder affecting the aorta and its branches.
  • RESULTS: Patients with severe arterial calcification showed lower BMD values than controls in lumbar spine (0.965 +/- 0.055 vs 1.126 +/- 0.153 g/cm2, P = 0.009) and total body (0.993 +/- 0.065 vs 1.085 +/- 0.082 g/cm2, P = 0.019).
  • [MeSH-major] Aortic Diseases / etiology. Bone Diseases, Metabolic / complications. Calcinosis / etiology. Carrier Proteins / blood. Membrane Glycoproteins / blood. Takayasu Arteritis / complications
  • [MeSH-minor] Adult. Bone Density. Female. Glycoproteins / blood. Humans. Lumbar Vertebrae / physiopathology. Osteoprotegerin. Premenopause. RANK Ligand. Receptor Activator of Nuclear Factor-kappa B. Receptors, Cytoplasmic and Nuclear / blood. Receptors, Tumor Necrosis Factor / blood

  • Genetic Alliance. consumer health - Takayasu arteritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219645.001).
  • [ISSN] 1462-0324
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Membrane Glycoproteins; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF11A protein, human; 0 / TNFRSF11B protein, human; 0 / TNFSF11 protein, human
  •  go-up   go-down


79. Zhou MS, Schulman IH, Raij L: Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens; 2010 Mar;28(3):527-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Hypertensive Dahl salt-sensitive rats manifested impaired endothelium-dependent relaxation to acetylcholine, aortic hypertrophy (35%), increased plasma C-reactive protein (25%), vascular superoxide (O2) production (148%), and expression of monocyte chemoattractant protein-1, tumor necrosis factor alpha, phospho-I kappaB alpha, and phospho-(Ser536)-p65NF kappaB.
  • Pyrrolidine dithiocarbamat significantly improved endothelium-dependent relaxation, reduced vascular O2, and normalized aortic hypertrophy and systemic and local inflammation, despite only mildly reducing blood pressure.
  • [MeSH-minor] Animals. Blood Pressure. Body Weight. C-Reactive Protein / metabolism. Chemokine CCL2 / metabolism. Insulin / physiology. Male. Nitric Oxide Synthase Type III / metabolism. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Rats. Rats, Inbred Dahl. Rats, Sprague-Dawley. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898250.001).
  • [ISSN] 1473-5598
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CCL2; 0 / Insulin; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 451W47IQ8X / Sodium Chloride; 9007-41-4 / C-Reactive Protein; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


80. Alaoui M, Bouzarwata A, El Idrissi R, Benzirare A, Sedki N, Sefiani Y, Lekehal B, Ammar F, Bensaid Y: [Multiple paragangliomas: about two cases]. Arch Mal Coeur Vaiss; 2007 Jun-Jul;100(6-7):582-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The carotid and jugulo-tympanic localization are the most frequent, and the aortic localization is very infrequent.
  • The first case is a 44 years-old woman, who presented a double localization: carotid (bilateral) and aortic (arch).
  • The second case is a patient with a double aortic localization, carotid and aortic, associated to a tympano-jugular localization.
  • [MeSH-major] Carotid Body Tumor / diagnosis. Glomus Jugulare Tumor / diagnosis. Glomus Tympanicum Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893641.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


81. Liu JH, Shen JM, Li L, Chang YT: [Effects of fentanyl on cytokines and MDA during cardiopulmonary bypass in patients undergoing valve replacement]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Feb;30(1):80-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blood Samples were taken before the operation (T1 ), before the CPB ( T2 ), 30 min after aortic declamping (T3 ) , 2 h after aortic declamping (T4 ), and 24 h (T5 ) after the operation for determination of plasma levels of tumor necrosis factor (TNF-alpha), interteukin IL-6 and IL-10, MDA.
  • RESULTS: There was no significant change in the age, body weight, aortic cross-clomp time, CPB time, and operation time.
  • [MeSH-major] Cardiopulmonary Bypass. Fentanyl / pharmacology. Heart Valve Prosthesis Implantation. Interleukin-6 / blood. Malondialdehyde / blood. Tumor Necrosis Factor-alpha / metabolism

  • Hazardous Substances Data Bank. FENTANYL .
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871195.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 4Y8F71G49Q / Malondialdehyde; 7E4PHP5N1D / Vecuronium Bromide; UF599785JZ / Fentanyl
  •  go-up   go-down


82. Rais H, Elmansouri F, Belaabidia B, Essadki O, Oussehal A, Sarf I: [Paratesticular desmoplastic small round cell tumour: case report with literature review]. Cancer Radiother; 2010 Apr;14(2):111-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular desmoplastic small round cell tumour: case report with literature review].
  • However, in recent years there have been reports on desmoplastic small round cell tumors affecting other body regions, including the paratesticular area.
  • We report the case of a 27-year-old male who consulted on a progressive enlargement of the right hemiscrotum.
  • A computed tomography scan showed a para-aortic mass of 1cm.
  • Histological and immunohistochemical diagnosis confirmed a desmoplastic small round cell tumor.
  • Today, 6 months after diagnosis the patient remains well and free of disease.
  • We should include this lesion among the differential diagnosis of paratesticular tumors, mainly in children and adolescents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009. Published by Elsevier SAS.
  • (PMID = 20189431.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


83. Paik KY: [Paraganglioma of the pancreas metastasized to the adrenal gland: a case report]. Korean J Gastroenterol; 2009 Dec;54(6):409-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraganglioma of the pancreas metastasized to the adrenal gland: a case report].
  • Paraganglioma is a rare neuroendocrine tumor arising from the neural crest, which includes tissues such as the adrenal medulla, carotid and aortic body, organs of Zuckerkandl, and other unnamed paraganglia.
  • The head, neck, and retroperitoneum are the most common sites for paraganglioma.
  • However, paraganglioma of the pancreas is extremely rare.
  • On the basis of these findings, we diagnosed the tumor as a paraganglioma of the pancreas and adrenal gland.
  • We report the first case of pancreas paraganglioma in Korea.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Paraganglioma / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Aged. Chromogranin A / metabolism. Female. Humans. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism. Synaptophysin / metabolism. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026898.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / S100 Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


84. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K: [Prostatic carcinoma that arose with hearing loss: a case report]. Hinyokika Kiyo; 2007 Jun;53(6):413-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whole body CT showed systemic lymphadenopathies (subclavian, para-aortic, and bilateral iliac LNs) and prostatic swelling with multiple pelvic masses.
  • Despite SCC histology, prostate-specific antigen (PSA) and androgen receptor (AR) were also expressed in -20% and -70% of tumor cells, respectively.
  • He is alive (39 months after diagnosis) with cancer.
  • Widespread metastases at the time of diagnosis were compatible with SCC.
  • Even though the initial symptoms are atypical for a prostatic carcinoma, SCC of prostate needs to be included as a rare differential diagnosis.


85. Kadl A, Pontiller J, Exner M, Leitinger N: Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock; 2007 Nov;28(5):582-8
MedlinePlus Health Information. consumer health - Antioxidants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mice were challenged with sublethal doses (2 mg/kg body weight) of LPS, and the effects of intravenously administered bilirubin (40 mg/kg body weight) were assessed.
  • Moreover, bilirubin inhibited LPS-induced expression of inflammatory genes in isolated cultured aortic endothelial cells and in bone marrow-derived macrophages.
  • [MeSH-minor] Animals. Biliverdine / blood. Cell Adhesion Molecules / biosynthesis. Cell Communication / drug effects. Cells, Cultured. Disease Models, Animal. Endothelial Cells / metabolism. Endothelial Cells / pathology. Gene Expression Regulation / drug effects. Inflammation Mediators / metabolism. Interleukin-1beta / biosynthesis. Leukocytes / metabolism. Leukocytes / pathology. Lipopolysaccharides / toxicity. Lung / metabolism. Lung / pathology. Lung Injury. Macrophages / metabolism. Macrophages / pathology. Male. Mice. Mice, Inbred BALB C. Rats. Time Factors. Tumor Necrosis Factor-alpha / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577133.001).
  • [ISSN] 1073-2322
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Cell Adhesion Molecules; 0 / Inflammation Mediators; 0 / Interleukin-1beta; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha; O9MIA842K9 / Biliverdine; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


86. Matoba M, Kitadate M, Kondou T, Yokota H, Tonami H: Depiction of hypervascular hepatocellular carcinoma with 64-MDCT: comparison of moderate- and high-concentration contrast material with and without saline flush. AJR Am J Roentgenol; 2009 Sep;193(3):738-44
Hazardous Substances Data Bank. SODIUM CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all protocols, the same iodine load per kilogram of body weight (516 mg/kg) was administered for the same injection duration (30 seconds).
  • Enhancement values in the aorta, liver, and portal vein and tumor-liver contrast were measured at multiphase CT.
  • RESULTS: Aortic enhancement was significantly different between protocols A and B (p = 0.04, p < 0.0001) and protocols B and C (p = 0.02, p < 0.001) in the first and second phases.
  • Tumor-liver contrast was significantly different between protocols A and B (p = 0.03, p = 0.02) and protocols B and C (p = 0.03, p = 0.04) in the first and second phases but not between protocols A and C.
  • CONCLUSION: Use of moderate concentration was more effective than use of a high concentration of contrast material for depiction of hepatocellular carcinoma.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696287.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 451W47IQ8X / Sodium Chloride; JR13W81H44 / Iopamidol
  •  go-up   go-down


87. Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA, Krieger M, Wagner DD: Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis. Circ Res; 2008 Sep 12;103(6):598-605
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prdx1 is known to be important to protect red blood cells against reactive oxygen species and in tumor prevention.
  • Indeed, endothelial P-selectin, soluble P-selectin, and von Willebrand factor in plasma were increased in Prdx1(-/-) mice compared to Prdx1(+/+) mice, indicating elevated Weibel-Palade body release.
  • Prdx1(-/-)/apoE(-/-) mice fed normal chow developed larger, more macrophage-rich aortic sinus lesions than Prdx1(+/+)/apoE(-/-) mice, despite similar amounts and size distributions of cholesterol in their plasma lipoproteins.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Circ Res. 2008 Sep 12;103(6):571-2 [18796643.001]
  • (PMID = 18689572.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL066105; United States / NHLBI NIH HHS / HL / R37 HL041002; United States / NHLBI NIH HHS / HL / R01 HL041002; United States / NIEHS NIH HHS / ES / F32 ES011586; United States / NHLBI NIH HHS / HL / P01 HL066105; United States / NCI NIH HHS / CA / CA077691; United States / NCI NIH HHS / CA / R01 CA077691
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Inflammation Mediators; EC 1.11.1.15 / Peroxiredoxins; EC 1.11.1.15 / Prdx1 protein, mouse
  • [Other-IDs] NLM/ NIHMS787602; NLM/ PMC4911701
  •  go-up   go-down


88. Potteaux S, Combadière C, Esposito B, Lecureuil C, Ait-Oufella H, Merval R, Ardouin P, Tedgui A, Mallat Z: Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol; 2006 Aug;26(8):1858-63
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 12 weeks of fat diet, CCR5 deficiency also resulted in 30% decrease of plaque-macrophage accumulation (P<0.005), associated with 16% reduction in lesion size in the aortic sinus (P=0.13), despite a significant increase in total cholesterol levels (P=0.03).
  • In addition, we found enhanced IL-10 production by CCR5-deficient peritoneal macrophages and decreased tumor necrosis factor (TNF)-alpha production by CCR5-/- T cells in comparison with CCR5+/+ controls.
  • [MeSH-minor] Animals. Chimera. Collagen / metabolism. Diet, Atherogenic. Female. Inflammation / pathology. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763157.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CCR5; 0 / Receptors, LDL; 9007-34-5 / Collagen
  •  go-up   go-down


89. Miroslav M, Lazar D, Aleksandar M, Predrag D, Svetozar P: Rare forms of peripheral arterial embolism: review of 11 cases. Vascular; 2005 Jul-Aug;13(4):222-9
Genetic Alliance. consumer health - Embolism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three patients were operated on owing to a foreign body embolism, two owing to a septic embolism, three owing to emboli that originated from malignant tissues, two owing to an embolization from cardiac myxoma, and one owing to an embolism from a myxomatous atrial septal defect.
  • Surgical treatment included foreign body extraction in three cases; thromboembolectomy in seven cases, and artery resection and saphenous graft interposition in one patient with septic embolism.
  • In addition, three cardiosurgical procedures were done: aortic valve replacement in the patient with a septic embolism and tumor excision in patients with atrial myxoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229795.001).
  • [ISSN] 1708-5381
  • [Journal-full-title] Vascular
  • [ISO-abbreviation] Vascular
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Shimizu J, Ikeda C, Arano Y, Adachi I, Morishita M, Yamaguchi S, Ishikawa N, Watanabe G, Minato H: Advanced lung cancer invading the left atrium, treated with pneumonectomy combined with left atrium resection under cardiopulmonary bypass. Ann Thorac Cardiovasc Surg; 2010 Aug;16(4):286-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent left pneumonectomy combined with LA resection using cardiopulmonary bypass (CPB), without aortic clamping, through left posterolateral thoracotomy under hypothermia (32 °C).
  • The tumor-invaded LA was resected in a 3.5 × 3.0 cm area, with vascular clamping, and the stump was closed with 3-0 Prolene sutures.
  • The surgical margin was free of tumor cells, and the duration of CPB was 28 minutes.
  • If CPB is used, the tension of the LA is removed by blood extraction into the bypass, and bradycardia is induced by a reduction of body temperature, probably reducing the risk of clamp dislocation.
  • [MeSH-minor] Aged. Cardiac Surgical Procedures. Cardiopulmonary Bypass. Heart Atria / pathology. Humans. Male. Neoplasm Invasiveness. Pneumonectomy

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057449.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. González-Navarro H, Abu Nabah YN, Vinué A, Andrés-Manzano MJ, Collado M, Serrano M, Andrés V: p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol; 2010 May 18;55(20):2258-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The goal of this study was to investigate the role in atherosclerosis of the tumor suppressor protein ARF (human p14(ARF), mouse p19(ARF)) encoded by the CDKN2A gene.
  • METHODS: Atherosclerosis-prone apolipoprotein E (apoE)-null and doubly deficient apoE-p19(ARF) mice were fed an atherogenic diet and sacrificed to quantify atherosclerosis burden in whole-mounted aortas and in aortic cross-sections.
  • RESULTS: Genetic disruption of p19(ARF) in apoE-null mice augments aortic atherosclerosis without affecting body weight, plasma lipoproteins, or plaque's proliferative activity.


92. Matsuyama S, Shimonishi T, Yoshimura H, Higaki K, Nasu K, Toyooka M, Aoki S, Watanabe K, Sugihara H: An autopsy case of granulocyte-colony-stimulating-factor-producing extrahepatic bile duct carcinoma. World J Gastroenterol; 2008 May 14;14(18):2924-7
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 79-year-old man was referred to this department due to the presence of extrahepatic bile duct carcinoma with a tumor at the left chest wall.
  • An autopsy showed a poorly differentiated adenocarcinoma with sarcomatous change, which had slightly invaded into the pancreas around the bile duct, and was found in the distal bile duct with multiple metastases to the chest wall, lung, kidney, adrenal body, liver, mesentery, vertebra and mediastinal and para-aortic lymph nodes, without locoregional lymph node and liver metastasis.
  • Since G-CSF-producing carcinoma and sarcomatous change of the biliary tract leads to poor prognosis, early diagnosis and treatment are needed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / metabolism. Bile Ducts, Extrahepatic / metabolism. Granulocyte Colony-Stimulating Factor / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Jpn. 1990 Dec;25(6):762-7 [1703976.001]
  • [Cites] Jpn J Clin Oncol. 1986 Mar;16(1):87-96 [3486302.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):187-91 [9700579.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):273-5 [9934773.001]
  • [Cites] Surg Today. 2005;35(7):590-3 [15976958.001]
  • [Cites] J Gastroenterol. 2005 Dec;40(12):1158-9 [16378181.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):246-9 [16850133.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):383-7 [10985899.001]
  • [Cites] Cell Tissue Res. 2000 Sep;301(3):353-67 [10994781.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):956-61 [11020857.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):191-5 [11504376.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1751-4 [12397785.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1337-44 [14691921.001]
  • [Cites] Int J Cell Cloning. 1985 Sep;3(5):294-303 [3900241.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1872-7 [7689920.001]
  • (PMID = 18473424.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2710741
  •  go-up   go-down


93. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS: Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs; 2005;5(3):141-54
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, testosterone treatment is reported to reduce serum levels of the pro-inflammatory cytokines interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha, and to increase levels of the anti-inflammatory cytokine IL-10; to reduce vascular cell adhesion molecule (VCAM)-1 expression in aortic endothelial cells; to promote vascular smooth muscle and endothelial cell proliferation; to induce vasodilatation and to improve vascular reactivity, to reduce serum levels of the pro-thrombotic factors plasminogen activator inhibitor (PAI)-1 and fibrinogen; to reduce low-density lipoprotein-cholesterol (LDL-C); to improve insulin sensitivity; and to reduce body mass index and visceral fat mass.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901202.001).
  • [ISSN] 1175-3277
  • [Journal-full-title] American journal of cardiovascular drugs : drugs, devices, and other interventions
  • [ISO-abbreviation] Am J Cardiovasc Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Cholesterol, LDL; 0 / Cytokines; 3XMK78S47O / Testosterone
  • [Number-of-references] 188
  •  go-up   go-down


94. Schima W, Hammerstingl R, Catalano C, Marti-Bonmati L, Rummeny EJ, Montero FT, Dirisamer A, Westermayer B, Bellomi M, Brisbois D, Chevallier P, Dobritz M, Drouillard J, Fraioli F, Jesus Martinez M, Morassut S, Vogl TJ: Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate. AJR Am J Roentgenol; 2006 Jun;186(6):1571-9
Hazardous Substances Data Bank. Iodixanol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were randomized to receive iodixanol, 320 mg I/mL (1.5 mL/kg body weight), at a flow rate of 3 mL/sec (48 patients) or 5 mL/sec (49 patients).
  • Qualitative (lesion detection, image quality) and quantitative (liver and aortic enhancement, tumor-liver contrast) analyses and safety assessment were performed.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714645.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Triiodobenzoic Acids; 92339-11-2 / iodixanol
  •  go-up   go-down


95. Osborne RF: Solitary fibrous tumor of the carotid sheath. Ear Nose Throat J; 2006 Jul;85(7):423-4
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the carotid sheath.
  • [MeSH-major] Fibroma / diagnosis. Head and Neck Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, CD34 / analysis. Aortic Bodies / pathology. Biopsy, Needle. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Carotid Body Tumor / diagnosis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Neurilemmoma / diagnosis. Neurilemmoma / surgery. Neurofibroma / diagnosis. Neurofibroma / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909808.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down






Advertisement